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A B S T R A C T
Background
Epilepsy is a common neurological disease that affects approximately 1% of the UK population. Approximately one-third of these
people continue to have seizures despite drug treatment. Pregabalin is one of the newer antiepileptic drugs which have been developed
to improve outcomes.
This is an updated version of the Cochrane Review published in Issue 3, 2014, and includes three new studies.
Objectives
To assess the efficacy and tolerability of pregabalin when used as an add-on treatment for drug-resistant focal epilepsy.
Search methods
For the latest update we searched theCochrane Register of Studies (CRSWeb), which includes the Cochrane EpilepsyGroup Specialized
Register and the Cochrane Central Register of Controlled Trials (CENTRAL), on 5 July 2018, MEDLINE (Ovid, 1946 to 5 July
2018), ClinicalTrials.gov (5 July 2018), and the World Health Organization International Clinical Trials Registry Platform (ICTRP,
5 July 2018), and contacted Pfizer Ltd, manufacturer of pregabalin, to identify published, unpublished, and ongoing trials.
Selection criteria
We included randomised controlled trials comparing pregabalin with placebo or an alternative antiepileptic drug as an add-on for people
of any age with drug-resistant focal epilepsy. Double-blind and single-blind trials were eligible for inclusion. The primary outcome
was 50% or greater reduction in seizure frequency; secondary outcomes were seizure freedom, treatment withdrawal for any reason,
treatment withdrawal due to adverse effects, and proportion of individuals experiencing adverse effects.
Data collection and analysis
Two review authors independently selected and assessed trials for eligibility and extracted data. Analyses were by intention-to-treat.
We presented results as risk ratios (RR) and odds ratios (OR) with 95% confidence intervals (CIs). Two review authors assessed the
included studies for risk of bias using the Cochrane ’Risk of bias’ tool.
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Main results
We included nine industry-sponsored randomised controlled trials (3327 participants) in the review. Seven trials compared pregabalin
to placebo. For the primary outcome, participants randomised to pregabalin were significantly more likely to attain a 50% or greater
reduction in seizure frequency compared to placebo (RR 2.28, 95% CI 1.52 to 3.42, 7 trials, 2193 participants, low-certainty evidence).
The odds of response doubled with an increase in dose from 300 mg/day to 600 mg/day (OR 1.99, 95% CI 1.74 to 2.28), indicating
a dose-response relationship. Pregabalin was significantly associated with seizure freedom (RR 3.94, 95% CI 1.50 to 10.37, 4 trials,
1125 participants, moderate-certainty evidence). Participants were significantly more likely to withdraw from pregabalin treatment
than placebo for any reason (RR 1.35, 95% CI 1.11 to 1.65, 7 trials, 2193 participants, moderate-certainty evidence) and for adverse
effects (RR 2.65, 95% CI 1.88 to 3.74, 7 trials, 2193 participants, moderate-certainty evidence).
Three trials compared pregabalin to three active-control drugs: lamotrigine, levetiracetam, and gabapentin. Participants allocated to
pregabalin were significantly more likely to achieve a 50% or greater reduction in seizure frequency than those allocated to lamotrigine
(RR 1.47, 95%CI 1.03 to 2.12, 1 trial, 293 participants) but not those allocated to levetiracetam (RR 0.94, 95%CI 0.80 to 1.11, 1 trial,
509 participants) or gabapentin (RR 0.96, 95% CI 0.82 to 1.12, 1 trial, 484 participants). We found no significant differences between
pregabalin and lamotrigine (RR 1.39, 95% CI 0.40 to 4.83) for seizure freedom, however, significantly fewer participants achieved
seizure freedom with add-on pregabalin compared to levetiracetam (RR 0.50, 95% CI 0.30 to 0.85). No data were reported for this
outcome for pregabalin versus gabapentin. We found no significant differences between pregabalin and lamotrigine (RR 1.07, 95% CI
0.75 to 1.52), levetiracetam (RR 1.03, 95% CI 0.71 to 1.49), or gabapentin (RR 0.78, 95% CI 0.57 to 1.07) for treatment withdrawal
due to any reason or due to adverse effects (pregabalin versus lamotrigine: RR 0.89, 95% CI 0.53 to 1.48; versus levetiracetam: RR
1.29, 95% CI 0.66 to 2.54; versus gabapentin: RR 1.07, 95% CI 0.54 to 2.11). Ataxia, dizziness, somnolence, weight gain, and fatigue
were significantly associated with pregabalin.
We rated the overall risk of bias in the included studies as low or unclear due to the possibility of publication bias and lack of
methodological details provided. We rated the certainty of the evidence as very low to moderate using the GRADE approach.
Authors’ conclusions
Pregabalin, when used as an add-on drug for treatment-resistant focal epilepsy, is significantly more effective than placebo at producing
a 50% or greater seizure reduction and seizure freedom. Results demonstrated efficacy for doses from 150 mg/day to 600 mg/day, with
increasing effectiveness at 600 mg doses, however issues with tolerability were noted at higher doses. The trials included in this review
were of short duration, and longer-term trials are needed to inform clinical decision making.
P L A I N L A N G U A G E S U M M A R Y
Pregabalin add-on for drug-resistant focal epilepsy
Review question
This review aimed to assess the effectiveness and tolerability of pregabalin when used as an add-on antiepileptic drug in treatment-
resistant focal epilepsy.
Background
Epilepsy is a common chronic neurological disease that affects approximately 1% of people in the UK. Approximately 1 in 400 people
with epilepsy have seizures that continue despite antiepileptic drug treatment (drug-resistant epilepsy). A number of new antiepileptic
drugs have been developed to treat epilepsy, of which pregabalin is one. Use of pregabalin in combination with other antiepileptic drugs
can reduce the frequency of seizures, but has some adverse effects.
Study characteristics
This review examined data from 9 trials including a total of 3327 participants. Study participants were assigned using a randommethod
to take pregabalin, placebo, or another antiepileptic drug in addition to their usual antiepileptic drugs.
Key results
Participants taking pregabalin were more than twice as likely to have their seizure frequency reduced by 50% or more during a 12-
week treatment period compared to those taking placebo, and were nearly four times more likely to be completely free of seizures.
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Pregabalin was shown to be effective across a range of doses (150 mg to 600 mg), with increasing effectiveness at higher doses. There was
also an increased likelihood of treatment withdrawal with pregabalin. Side effects associated with pregabalin included ataxia, dizziness,
fatigue, somnolence, and weight gain. When pregabalin was compared to three other antiepileptic drugs (lamotrigine, levetiracetam,
and gabapentin), participants taking pregabalin were more likely to achieve a 50% reduction in seizure frequency than those taking
lamotrigine. We found no significant differences between pregabalin and levetiracetam or gabapentin as add-on drugs.
Certainty of the evidence
We rated all included studies as at low or unclear in risk of bias due to missing information about the methods used to conduct the trial
and a suspicion of publication bias. Publication bias can occur when studies that report non-significant findings are not published. We
suspected publication bias because the majority of included studies showed significant findings and were sponsored by the same drug
company. We assessed the certainty of the evidence for the primary outcome of reduction in seizure frequency as low, meaning that we
cannot be certain that the finding reported is accurate. However, we rated the certainty of the evidence for the outcomes seizure freedom
and treatment withdrawal as moderate, so we can be fairly confident that these results are accurate. There were no data regarding the
longer-term effectiveness of pregabalin, which should be investigated in future studies.
The evidence is current to 5 July 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Pregabalin compared to placebo for drug- resistant focal epilepsy
Patient or population: drug-resistant focal epilepsy
Setting: outpat ient sett ing
Intervention: pregabalin
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with pregabalin
50% or greater reduc-
tion in seizure fre-
quency - ITT analysis
Follow-up: range 12 to
17 weeks
Study population RR 2.28
(1.52 to 3.42)
2193
(7 RCTs)
⊕⊕©©
LOW 12356
Pregabalin may in-
crease the proport ion
of people achieving
50% or greater reduc-
t ion in seizure f re-
quency according to
ITT analysis, but we are
uncertain
184 per 1000 420 per 1000
(280 to 631)
50% or greater reduc-
tion in seizure fre-
quency - best-case
analysis
Follow-up: range 12 to
17 weeks
Study population RR 3.57
(2.17 to 5.86)
2193
(7 RCTs)
⊕©©©
VERY LOW 1235
Pregabalin may in-
crease the proport ion
of people achieving
50% or greater reduc-
t ion in seizure f re-
quency according to
best-case analysis, but
we are very uncertain
184 per 1000 658 per 1000
(400 to 1000)
50% or greater reduc-
tion in seizure fre-
quency - worst-case
analysis
Follow-up: range 12 to
17 weeks
Study population RR 1.15
(0.92 to 1.43)
2193
(7 RCTs)
⊕©©©
VERY LOW 12
Pregabalin might have
no ef fect on the
proport ion of peo-
ple achieving 50% or
greater reduct ion in
seizure f requency ac-
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cording to worst-case
analysis, however, we
are very uncertain
345 per 1000 397 per 1000
(318 to 494)
Seizure freedom
Follow-up: 12 weeks
Study population RR 3.94
(1.50 to 10.37)
1125
(4 RCTs)
⊕⊕⊕©
MODERATE 145
Pregabalin likely in-
creases the number
of people achieving
seizure f reedom
11 per 1000 42 per 1000
(16 to 112)
Treatment withdrawal
for any reason
Follow-up: range 12 to
17 weeks
Study population RR 1.35
(1.11 to 1.65)
2193
(7 RCTs)
⊕⊕⊕©
MODERATE 1
Pre-
gabalin likely slight ly in-
creases the number of
people who withdraw
f rom treatment for any
reason, however this ef -
fect may or may not be
important
161 per 1000 217 per 1000
(178 to 265)
Treatment withdrawal
due to adverse effects
Follow-up: range 12 to
17 weeks
Study population RR 2.65
(1.88 to 3.74)
2193
(7 RCTs)
⊕⊕⊕©
MODERATE 145
Pregabalin likely in-
creases the number
of people withdrawing
f rom treatment due to
adverse ef fects
53 per 1000 141 per 1000
(100 to 199)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; ITT: intent ion-to-treat; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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1Downgraded once for risk of bias: two studies did not conf irm their method of randomisat ion; all studies failed to specif y
method of allocat ion concealment; three studies did not provide information on method of blinding; and two studies were
judged to be at risk of other sources of bias.
2Downgraded twice for inconsistency: signif icant heterogeneity (P < 0.05) was detected within the data set.
3Downgraded once for publicat ion bias: publicat ion bias suspected.
4Downgraded once for imprecision: number of events reported (< 400) did not suf f ice the opt imal information size.
5Upgraded once for large ef fect: risk rat io was greater than 2.00.
6Upgraded once for dose response: dose-response relat ionship was conf irmed by regression model.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Epilepsy is a common neurological chronic condition that affects
approximately 1% of the UK population (Hauser 1990). A single
antiepileptic drug (AED) (monotherapy) can induce remission for
the majority of those diagnosed. However, up to 30% of people
with epilepsy fail to respond to monotherapy (Cockerell 1995).
Patients who have failed to respond to a minimum of two AEDs
given as monotherapy are considered to be ’drug-resistant’. The
majority of those who are drug-resistant have focal onset (also
called focal- or localisation-related) seizures. During focal-onset
seizures, abnormal electrical activity initiates in one part of the
brain, and during the course of the seizure the abnormal electrical
activity either remains localised or spreads to other parts of the
brain (Ramaratnam 2016). For individuals with drug-resistant fo-
cal epilepsy, recurrent seizures can reduce quality of life, and may
also lead to injuries, social isolation, and depression (Villeneuve
2004). Individuals with this neurological condition pose a signif-
icant therapeutic problem, which has led to the development of
new AEDs as well as exploration of non-pharmacological treat-
ment options, such as vagal nerve stimulation and epilepsy surgery
(Panebianco 2015; West 2015). Over the past two decades, the
introduction of several new antiepileptic drugs that often are bet-
ter tolerated and more manageable than older AEDs has improved
the ability to treat individuals with epilepsy. Recent studies have
reported that 12% to 17% of treatment-resistant individuals be-
come seizure-free with the addition of a previously untried, in
most cases new-generation, antiepileptic drug (Granata 2009).
Description of the intervention
Since the 1990s, numerous new AEDs have become available
that aim to provide more potent and better-tolerated treatments
for epilepsy. Pregabalin is one of these new compounds with
antiepileptic, analgesic, and anxiolytic (anxiety-reducing) proper-
ties. Pregabalin has favourable pharmacokinetics: it is not protein
bound, is 90% bioavailable, and reaches peak plasma concentra-
tions within 1.5 hours of administration of an oral dose. With
repeated doses, a steady state is achieved within 24 to 48 hours.
Furthermore, 90% of the drug is eliminated, unmetabolised, by
the kidneys, and it has no known drug interactions (Brodie 2005).
Pregabalin was launched in the UK market in 2004 as an add-on
AED for focal-onset seizures, as well as a treatment for neuropathic
pain, and as an anxiolytic in 2006.
How the intervention might work
Pregabalin is structurally related to both the neurotransmitter
γ -aminobutyric acid (GABA), and the older antiepileptic drug,
gabapentin. Similar to gabapentin, the primarymechanismunder-
lying the pharmacological action of pregabalin does not appear to
involve the GABA system. In particular, pregabalin does not bind
to GABA-A, GABA-B, or benzodiazepine receptors. Pregabalin is
neither metabolically converted to GABA or to a GABA agonist,
nor does it have any effect on the uptake or degradation of GABA.
In fact, the primary mode of action of pregabalin is via the inhi-
bition of depolarisation-induced calcium influx at P-, Q-, and N-
type voltage-gated calcium channels, located at the nerve termi-
nals. At the molecular level, this action is achieved by pregabalin
binding to the α-2-δ subunit of voltage-gated calcium channels
(Ben-Menachem 2004). As a consequence of the reduced calcium
influx, less excitatory neurotransmitter, such as glutamate, is re-
leased from the presynaptic nerve terminals.This action is thought
to mediate its antiepileptic, anxiolytic, and analgesic properties.
In addition, by acting on AMPA (α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid) receptors, pregabalin indirectly reduces
synaptic noradrenaline release (Fink 2002).
Notably, the mechanism of action of pregabalin does not appear
to differ from that of gabapentin. The affinity of pregabalin for
the α-2-δ modulatory site, however, is much greater than that of
gabapentin. This explains why pregabalin is three- to six-fold more
potent than gabapentin in animal models of seizures and epilepsy,
and also in models of anxiety and neuropathic pain.
Why it is important to do this review
This review is an update of a previous Cochrane Review (Pulman
2014) and aims to summarise existing data regarding the effects
of add-on pregabalin for people with drug-resistant focal-onset
seizures. Clinical trials published on the antiepileptic properties
of pregabalin have so far focused on people with drug-resistant
focal-onset epilepsy. In these randomised placebo-controlled trials,
study participants are randomised to have either pregabalin or
placebo added to their existing AED treatment. This is in keeping
with international guidelines on the development of AEDs (ILAE
Commission 1989). Once a drug has confirmed efficacy and safety
as an add-on therapy, it can be tested as monotherapy. The use
of pregabalin as monotherapy has been addressed in a separate
Cochrane Review by Zhou 2012.
O B J E C T I V E S
To assess the efficacy and tolerability of pregabalin when used as
an add-on treatment for drug-resistant focal epilepsy.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
To be included in the review, studies had to meet the following
criteria:
1. randomised controlled trials;
2. double-blind or single-blinded trials;
3. placebo controlled or active controlled;
4. parallel-group or cross-over studies.
Types of participants
People of any age with drug-resistant focal epilepsy (i.e. experienc-
ing simple focal, complex focal, or secondary generalised tonic-
clonic seizures).
Types of interventions
1. The active-treatment group received pregabalin in addition
to an existing AED regimen taken at time of randomisation.
2. The control group received a matched placebo or an active
comparator control in addition to an existing AED regimen
taken at time of randomisation.
Types of outcome measures
Primary outcomes
50% or greater reduction in seizure frequency
We chose the proportion of people with a 50% or greater reduc-
tion in seizure frequency in the treatment period compared to the
pre-randomisation baseline period as the primary outcome. We
chose this because it is a commonly reported outcome, and can
be calculated for studies that do not report this outcome provided
that baseline seizure data were recorded.
Secondary outcomes
Seizure freedom
The proportion of participants with a complete cessation of
seizures during the treatment period.
Treatment withdrawal
We used the proportion of participants having treatment with-
drawn for any reason during the course of the treatment period as
a measure of global effectiveness. Treatment is likely to be with-
drawn due to adverse effects, lack of efficacy, or a combination
of both, and this is an outcome to which the individual makes
a direct contribution. In trials of short duration, it is likely that
adverse effects will be the most common reason for withdrawal.
We also assessed the proportion of participants having treatment
withdrawn for adverse effects.
Adverse effects
1. The proportion of participants experiencing the following
five adverse effects (we considered these adverse effects to be
common and important adverse effects of AEDs):
i) ataxia (co-ordination problems);
ii) dizziness;
iii) fatigue;
iv) nausea;
v) somnolence (unusual drowsiness).
2. The proportion of participants experiencing the five most
common adverse effects mentioned in the included trials if these
differed from those listed in (1) above.
Search methods for identification of studies
Electronic searches
We ran searches for the original review in 2007, and subsequent
searches in March 2010, September 2011, May 2012, January
2014, September 2015, and September 2016. For the latest update
we searched the following.
1. Cochrane Register of Studies (CRS Web, 5 July 2018),
which includes the Cochrane Epilepsy Group Specialized
Register and the Cochrane Central Register of Controlled Trials
(CENTRAL), using the search strategy outlined in Appendix 1.
2. MEDLINE (Ovid, 1946 to 5 July 2018) using the search
strategy outlined in Appendix 2.
3. ClinicalTrials.gov (5 July 2018) using the search strategy
outlined in Appendix 3.
4. World Health Organization International Clinical Trials
Registry Platform (ICTRP, 5 July 2018) using the search strategy
outlined in Appendix 4.
We did not impose any language restrictions.
Searching other resources
We reviewed the reference lists of retrieved studies to check for
additional reports of relevant studies. We also contacted Pfizer Ltd
(manufacturer of pregabalin) and colleagues in the field.
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Data collection and analysis
Selection of studies
For the update, two review authors (RB and MP) independently
assessed trials for inclusion. Any disagreements were resolved by
discussion with a third review author (AM). Two review authors
(RB and MP) extracted data and assessed risk of bias; again, dis-
agreements were resolved by discussion.
Data extraction and management
The same two review authors extracted the following information
from the included trials. Any disagreements were resolved by mu-
tual discussion.
Methodological/trial design
1. Method of randomisation and concealment.
2. Method of double-blinding.
3. Whether any participants had been excluded from the
reported analyses.
4. Duration of baseline period.
5. Duration of treatment period.
6. Dose(s) of pregabalin tested.
Participant/demographic information
1. Total number of participants allocated to each treatment
group.
2. Age/sex.
3. Number with focal/generalised epilepsy.
4. Seizure types.
5. Seizure frequency during the baseline period.
6. Number of background drugs.
For all trials sponsored by Pfizer Ltd, confirmation of the
following information
1. Method of randomisation.
2. Total number randomised to each group.
3. Number of participants in each group achieving a 50% or
greater reduction in seizure frequency.
4. Number of participants in each group having treatment
withdrawn postrandomisation.
5. For excluded participants:
i) the reason for exclusion;
ii) whether any of those excluded completed the
treatment phase;
iii) whether any of those excluded had a 50% or greater
reduction in seizure frequency during the treatment phase.
Outcomes
We recorded the number of participants experiencing each out-
come (see Types of outcome measures) per randomised group.
Assessment of risk of bias in included studies
For the update, two review authors (RB and MP) independently
assessed risk of bias for each trial using the Cochrane ’Risk of bias’
tool as described in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). Any disagreements were discussed
and resolved.We judged each included study to be at low, high, or
unclear risk of bias for the six domains applicable to randomised
controlled trials: randomisation method, allocation concealment,
blinding methods, incomplete outcome data, selective outcome
reporting, and other sources of bias.
Measures of treatment effect
We presented the primary outcome of seizure reduction as a risk
ratio.We also presented the secondary outcomes, including seizure
freedom, treatment withdrawal, and adverse effects, as risk ratios.
Unit of analysis issues
The inclusion of cross-over studies in meta-analyses introduces
unit of analysis issues because each patient contributes data to both
treatment groups. We had planned to extract data from the first
treatment period of any eligible cross-over studies, had any been
identified for inclusion. Essentially, we would have regarded the
first treatment period as a parallel study, thus preventing data from
the same patient being considered twice whilst simultaneously
avoiding any issues of carry-over effect. We did not include any
cross-over studies in this current review update, hence there were
no unit of analysis issues to consider.
Dealing with missing data
We sought any missing data from the study authors. We carried
out intention-to-treat (ITT), best-case, and worst-case analysis on
the primary outcome to account for any missing data. All analyses
are presented in the main report.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the distribution
of important participant factors amongst trials (e.g. age, seizure
type, duration of epilepsy, number of antiepileptic drugs taken at
the time of randomisation) and trial factors (e.g. allocation con-
cealment, blinding, losses to follow-up). We examined statistical
heterogeneity using a Chi2 test and the I2 statistic for heterogene-
ity and, providing no significant heterogeneity was present (P >
0.10), we employed a fixed-effect model. In the event that we
found heterogeneity (P < 0.10), we planned to use a random-ef-
fects model analysis employing the inverse-variance method.
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Assessment of reporting biases
We requested protocols from study authors to enable a compar-
ison of outcomes of interest. We investigated outcome reporting
bias using the Outcome Reporting Bias in Trials (ORBIT I) ma-
trix system for benefit outcomes, Kirkham 2010, and ORBIT II
matrix system for harm outcomes (Saini 2014). We examined the
asymmetry of funnel plots to detect any publication bias.
Data synthesis
We employed a fixed-effect model meta-analysis to synthesise the
data. Comparisons we expected to carry out included:
1. pregabalin intervention group versus placebo control group;
2. pregabalin intervention group versus active-comparator
control group.
We planned to stratify each comparison by study characteristics,
such as dose of pregabalin used, during subgroup analysis to ensure
the appropriate combination of study data.
Our preferred estimator was the Mantel-Haenszel risk ratio (RR).
For the outcomes 50% or greater reduction in seizure frequency
and treatment withdrawal, we used 95% confidence intervals
(CIs). For individual adverse effects, we used 99% CIs to make an
allowance for multiple testing.
Our analyses included all participants in the treatment group to
which they had been allocated. For the efficacy outcome (50%
or greater reduction in seizure frequency), we undertook three
analyses:
1. Primary (ITT) analysis: participants not completing follow-
up or with inadequate seizure data were assumed to be non-
responders. Analysis by ITT was reported by all of the included
studies.
2. Worst-case analysis: participants not completing follow-up
or with inadequate seizure data were assumed to be non-
responders in the intervention group, and responders in the
placebo group.
3. Best-case analysis: participants not completing follow-up or
with inadequate seizure data were assumed to be responders in
the intervention group, and non-responders in the placebo
group.
The purpose of the best-case and worst-case analyses is to test the
whether the assumption that all participants not completing fol-
low-up or with inadequate seizure data are non-responders, made
during ITT analysis, affects the estimated effect size.
Dose regression analysis
Dose-response analysis was evaluated using a generalised linear
mixed model (i.e. a model including both fixed and random ef-
fects) with the logit link function, as described in Turner 2000,
and estimated using the command xtmelogit in STATA SE version
14 (Stata statistical software 2015). Study and dose were included
as fixed effects within the mixed model whilst treatment was in-
cluded as a random-effect within the mixed model (no random-
effect was included for the constant term of the mixed model).
Dose was standardised by its standard deviation (245 mg). This
method estimated an odds ratio (OR) as opposed to a RR.
Subgroup analysis and investigation of heterogeneity
We undertook subgroup analysis for all of the outcomes included
in this review. For the comparison pregabalin versus placebo, sub-
group analysis was stratified by dose of pregabalin. Dose of prega-
balinwas chosen because it was themost striking clinical difference
identified between the included studies and was thus anticipated
to be the cause of any observed heterogeneity. For the comparison
pregabalin versus active comparator, subgroup analysis was strat-
ified by active comparator in order to determine whether prega-
balin might be advantageous or disadvantageous compared to a
specific alternative AED. If deemed appropriate, we intended to
investigate heterogeneity using sensitivity analysis.
Sensitivity analysis
We also intended to carry out sensitivity analysis if peculiarities
were found between study quality, characteristics of participants,
interventions, and outcomes. We did not find any peculiarities
between the studies, therefore no sensitivity analyses were con-
ducted.
Summarising and interpreting results
Weused theGRADE approach, as outlined in theGRADEHand-
book (Schünemann 2013), to interpret findings, and GRADEpro
GDT software (which imports data from Review Manager 5 soft-
ware (GRADEproGDT 2015)), to create a ’Summary of findings’
table for both comparisons: pregabalin versus placebo and prega-
balin versus active comparator. We GRADE-assessed the follow-
ing outcomes, deemed to be the most important: 50% of greater
reduction in seizure frequency (intention-to-treat, best-case, and
worst-case analysis), seizure freedom, treatment withdrawal for
any reason and treatment withdrawal due to adverse effects.We as-
sessed the evidence across eight criteria (risk of bias, inconsistency,
indirectness, imprecision, publication bias, effect size, presence of
plausible confounding factors, and dose-response gradient) to de-
termine its certainty.
R E S U L T S
Description of studies
Results of the search
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The searches conducted (September 2015, September 2016 and
July 2018), subsequent to the previously published search in Jan-
uary 2014, retrieved a total of 134 new records (see Figure 1). We
removed 50 duplicates and 59 obviously irrelevant records, prior
to any screening. This left 25 records to be evaluated based on title
and abstract. We removed 21 records, based on their title and ab-
stract, and subsequently assessed four records as full-text articles.
We excluded one record that was ineligible for inclusion (Taghdiri
2015). The other three studies (French 2014, French 2016 and
Zaccara 2014), however, satisfied all inclusion criteria and were
therefore included in the review.
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Figure 1. Study flow diagram showing the screening results from the searches conducted in: September
2015, September 2016, and July 2018.
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Included studies
We included nine randomised controlled trials (3327 participants)
with parallel-group design in the review, all of which were spon-
sored by the drug manufacturer Pfizer Ltd. All nine of the in-
cluded studies recruited participants with drug-resistant focal-on-
set seizures. Participants were taking between one and four AEDs
and had at least three, four, or six focal seizures per month in the
pre-randomisation baseline period. Further details are given be-
low and are summarised in the Characteristics of included studies
tables.
Arroyo and colleagues published a multicentre (45 sites in Europe,
Australia, and Africa) trial in 2004 that included 288 participants
(Arroyo 2004). Inclusion criteria were defined as people aged 18
years or older with focal-onset seizures. As an electroencephalo-
gram (EEG)was not required to confirm the diagnosis, some of the
18 participants who were stated as having “generalised seizures”,
rather than secondary generalised, may have had primary gener-
alised epilepsy. Participants were randomised to either 50 mg pre-
gabalin three times daily (n = 99); 200 mg pregabalin three times
daily (n = 92); or placebo three times daily (n = 97). After a baseline
assessment of eight weeks, the treatment period was conducted
over 12 weeks (including a titration period of four and eight days).
During the treatment period, participants were assessed weekly for
the first two weeks and fortnightly thereafter. Median follow-up
was 12 weeks (range one day to 12 weeks). Three time points were
reported in the study, each at four-weekly intervals.
Baulac and colleagues conducted amulticentre (97 sites in Europe,
Canada, and Australia) trial, comprising 434 participants (Baulac
2010). Randomised participants were between 16 and 82 years of
age and had undergone an EEG within two years prior to ran-
domisation. Treatment arms were 150 mg to 300 mg pregabalin
twice daily (n = 152); 150 mg to 200 mg lamotrigine twice daily
(n = 141); and placebo (n = 141). Following a six-week baseline
period, there was a 17-week double-blind treatment period com-
prising two phases. The first phase (phase I) spanned 11 weeks and
included an up-titration period (one week for pregabalin and five
weeks for lamotrigine). During phase I, participants randomised
to pregabalin and lamotrigine were both up-titrated to 300 mg/d
of their respective treatment drugs and were then maintained on
this dose. Participants who were seizure-free for the duration of
phase I continued to be maintained on 300 mg/d active treatment
for the duration of phase II (six weeks). Participants randomised
to pregabalin who continued to have seizures were further up-
titrated to 600 mg/d pregabalin during phase II, whereas partici-
pants randomised to lamotrigine who continued to have seizures
were up-titrated to 400 mg/d lamotrigine for the remaining six
weeks of the treatment period. Participant review time points and
follow-up were not reported.
Beydoun and colleagues randomised 313 participants, aged 17
to 82 years, from 43 US and Canadian centres in a randomised
placebo-controlled trial (Beydoun 2005). Treatment groups in-
cluded 200 mg pregabalin three times daily (n = 111); 300 mg pre-
gabalin twice daily (n = 104); and placebo (n = 98). After a baseline
assessment of eight weeks, the treatment period was conducted
over 12 weeks (including a one-week titration period). Follow-up
occurred on weeks two, four, eight, and 12. Median follow-up was
12 weeks (range not reported). During the trial an interim analysis
was carried out on 129 participants, which led to an alteration of
the subsequent statistical analysis.
Elger and colleagues reported amulticentre (53 sites inCanada and
Europe) trial of 341 participants, aged 17 to 78 years (Elger 2005).
Treatment arms were 150 mg to 600 mg pregabalin (n = 131),
titrated with respect to clinical response and adverse effects in 150
mg daily increments; fixed-dose pregabalin of 300 mg twice daily
(n = 137); and placebo (n = 73). Participants were randomised
to one of the three treatments using a 2:2:1 ratio, respectively.
The treatment period ran over 12 weeks and followed a six-week
baseline period. Participants were reviewed at two, four, eight, and
12 weeks into the study. Median follow-up was 12 weeks, and over
58% of participants completed the study in each arm. The range
of follow-up was not reported.
French and colleagues published a multicentre (76 sites in US
and Canada) trial that included 455 participants (French 2003).
Randomised participants were between 12 and 70 years of age, but
not all hadEEGand imagingdata. Thosewith absence seizures and
Lennox-Gastaut syndrome were excluded; however, the inclusion
of some patients with primary generalised epilepsy could not be
ruled out. Participants were randomised into one of five treatment
arms: 50 mg/day (n = 88), 150 mg/day (n = 88), 300 mg/day (n =
90), and 600 mg/day (n = 89) pregabalin in a twice-daily regimen,
and placebo (n = 100). Baseline assessment occurred over eight
weeks, and treatment duration was 12 weeks with no titration
period. Follow-up occurred on weeks two, four, eight, and 12.
Median follow-up was 12 weeks (range one day to 12 weeks).
Around 83% of participants completed the study.
French and colleagues published a multicentre (66 centres in the
USA, Europe, and Asia) trial that included 325 participants, aged
18 to 75 years (French 2014). Participants were randomised 1:
1:1 to controlled-release pregabalin 165 mg (n = 101), 330 mg
(n = 114), or placebo (n = 110). The trial ran over 23 weeks
including an eight-week baseline phase, a two-week double-blind
dose escalation, a 12-week double-blind maintenance phase, and
a one-week taper. The mean overall compliance was 99.2% for all
three treatment arms, as demonstrated by participant-completed
diaries.
French and colleagues conducted amulticentre (56 centres in East-
ern and Western Europe, Asia, South and Central America) trial
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that included 484 participants between 18 and 80 years of age
(French 2016). Participants were randomised 1:1 to pregabalin
450 mg/d (n = 241) or gabapentin 1500 mg/d (n = 241). The trial
included a six-week baseline phase (screening), a nine-week dou-
ble-blind dose escalation (titration) phase, and a 12-week double-
blind maintenance phase (21-week treatment phase overall). The
primary endpoint was the percentage change from baseline in 28-
day seizure rate to the treatment phase. Around 74% of partici-
pants completed the study.
Lee and colleagues conducted a multicentre (nine sites in Korea)
trial consisting of two treatment arms (Lee 2009). A total of 178
participants, aged 18 years and above, were randomised to either
75 mg to 300 mg pregabalin twice daily (n = 119) or placebo
(n = 59) using a 2:1 ratio. Following a six-week baseline period,
treatment was conducted over 12 weeks with a one-week taper
period at the end. Participants were assessed at weeks two, four,
six, eight, and 12 with a follow-up visit at week 13. Eighty-eight
per cent of randomised participants completed the study.
Zaccara and colleagues randomised 509 participants aged ≥ 18
from71 centres inEurope, theUSA, andAsia to one of two groups:
pregabalin (n= 254; median dose 450 mg) or levetiracetam (n =
255; median dose 2000 mg) (Zaccara 2014). The trial included a
six-week baseline phase, a four-week dose escalation phase, and a
12-week maintenance phase. During the trial an interim analysis
was carried out after approximately 50% of participants had com-
pleted the maintenance phase. The trial continued as planned.
Excluded studies
From the searches conducted since the previous review update,
it was clear that one previously ongoing trial (Bali 2012), has
since been published (Taghdiri 2015). This study was, however,
excluded due to the ineligibility regarding the study population.
Further details are provided in the Characteristics of excluded
studies table.
Studies awaiting classification
We assessed two studies as awaiting classification (see
Characteristics of studies awaiting classification table), as we have
obtained no additional information regarding either study since
the publication of the previous review (Russi 2006; Tata 2007).
Risk of bias in included studies
We assessed all nine included studies for risk of bias based on the
six domains of the Cochrane ’Risk of bias’ tool. See Characteristics
of included studies tables for each study for further details and
Figure 2 for ’Risk of bias’ graph and Figure 3 for ’Risk of bias’
summary.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Seven of the nine included studies employed an adequate method
of sequence generation by using computer-generated identifica-
tion numbers and block sizes of five or six (Arroyo 2004; Beydoun
2005; Elger 2005; French 2003; French 2014; French 2016;
Zaccara 2014), therefore we assessed them as being at low risk of
selection bias with regard to random sequence generation. Two of
the studies did not provide details regarding method of randomi-
sation and were judged as at unclear risk of bias (Baulac 2010; Lee
2009). None of the studies reportedmethods employed to prevent
foreknowledge of group assignment (allocation concealment), and
were therefore assessed as at unclear risk of bias for selection bias
with regard to allocation concealment.
Blinding
Six studies were reported as double-blinded with the use of iden-
tical tablets with identical packaging for all treatment groups
(Arroyo 2004; Beydoun 2005; Elger 2005; French 2003; French
2016; Zaccara 2014); we assessed these studies as at low risk of
performance and detection bias. Two studies were reported as dou-
ble-blinded, but no further details were provided (French 2014;
Lee 2009). Another study stated that the same number of capsules
per day were administered to each study group, however the study
did not specify whether the tablets were identical in appearance
(Baulac 2010). As a result, it was not clear whether blinding was
effectively maintained. We therefore assessed these three studies as
at unclear risk of performance and detection bias (Baulac 2010;
French 2014; Lee 2009).
Incomplete outcome data
All studies reported study attrition rates, and all studies used an
ITT analysis on randomised participants who took at least one
dose of medication, using the ’last observation carried forward’
approach (Arroyo 2004; Baulac 2010; Beydoun 2005; Elger 2005;
French 2003; French 2014; French 2016; Lee 2009), that is for
participants failing to complete follow-up, seizure-frequency data
were extrapolated from the last participant observation point for
the whole treatment period, whilst for participants with no seizure
data during the treatment period, baseline data were extrapolated.
In the trial reports a total of six participants were excluded from
analyses; these participants have been included in the denominator
as non-responders for the primary analysis.
Selective reporting
Most of the included studies distinguished between the primary
and secondary outcome variables. No trial protocols were available
for examination to compare reported outcomes, however all stud-
ies reported the primary/secondary outcomes stated in the meth-
ods section in the results section of the articles. Notably, all ex-
pected outcomes with respect to this review were reported, there-
fore we had no suspicions or concerns about any purposefully
withheld data.
Further to this, we also completed an outcome matrix (Figure 4)
according to the ORBIT I and ORBIT II matrix system to inves-
tigate the potential for outcome reporting bias (Kirkham 2010;
Saini 2014). Four included studies did not report seizure freedom
(Arroyo 2004; French 2003; French 2014; French 2016), how-
ever we did not find this to be concerning. All of the participants
in the included studies had drug-resistant epilepsy, meaning that
their epilepsy is refractory despite treatment with currently avail-
able antiepileptic medication. As a result, it is unlikely that many
patients will achieve seizure freedom. Instead, 50% or greater re-
duction in seizure frequency is a more clinically relevant efficacy
outcome for these patients. Consequently, it would be much more
concerning and suspicious if any of the included studies failed to
report the primary outcome, 50% or greater reduction in seizure
frequency.
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Figure 4. ORBIT matrix for review outcomes.
In addition, we noted that several of the included studies did not
report all of the adverse effects investigated as part of this review.
However, because the majority of other harms were fully reported,
we did not find this to be suspicious. The studies specified that
they only reported the most common adverse events, for example
only those reported by more than 5% of the study population,
thus further justifying the absence of some data.
We consequently rated all nine included studies as at low risk of
reporting bias.
Other potential sources of bias
In two included studies (Arroyo 2004; French 2003), individuals
with primary generalised epilepsy may have been included in the
trials, possibly leading to bias within the results, thus we assessed
these studies as at unclear risk of other bias. We detected no other
potential sources of bias for the remaining seven studies (Baulac
2010; Beydoun 2005; Elger 2005; French 2014; French 2016; Lee
2009; Zaccara 2014), resulting in a judgement of low risk of other
bias for these studies.
Effects of interventions
See: Summary of findings for the main comparison Pregabalin
compared to placebo for drug-resistant focal epilepsy; Summary
of findings 2Pregabalin compared to active comparators for drug-
resistant focal epilepsy
See Summary of findings for the main comparison for the main
comparison ’pregabalin versus placebo for refractory epilepsy’.
Pregabalin versus placebo control
Six included studies involving a total of 1868 randomised par-
ticipants compared immediate-release pregabalin versus placebo
(Arroyo 2004; Baulac 2010; Beydoun 2005; Elger 2005; French
2003; Lee 2009). Another study (French2014), including325par-
ticipants, compared controlled-release pregabalin versus placebo.
We included these seven trials in the analysis for the comparison
’pregabalin versus placebo’.
50% or greater reduction in seizure frequency
Seven included studies (2193 participants) reported this outcome
(Arroyo 2004; Baulac 2010; Beydoun 2005; Elger 2005; French
2003; French 2014; Lee 2009). An ITT analysis pooling all doses
(50 mg to 600 mg/day immediate- and controlled-release prega-
balin) showed evidence of heterogeneity (I2 = 80%), therefore we
employed a random-effects model. Participants allocated to pre-
gabalin were significantly more likely to achieve a 50% or greater
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reduction in seizure frequency than those allocated to placebo
(risk ratio (RR) 2.28, 95% confidence interval (CI) 1.52 to 3.42;
Analysis 1.1). Subgroup analyses assessing the effect of individual
doses showed no significant effect for 50 mg/d immediate-release
pregabalin (RR 1.06, 95% CI 0.52 to 2.12; Analysis 2.1). Higher
doses of immediate-release pregabalin were associated with a sig-
nificantly higher proportion of participants achieving a 50% or
greater reduction in seizure frequency compared to placebo (150
mg/d: RR 2.22, 95% CI 1.36 to 3.63; 300 mg/d: RR 2.86, 95%
CI 1.65 to 4.94; 600mg/d: RR4.62, 95%CI 3.34 to 6.39; titrated
150 mg/d to 600 mg/d: RR 1.76, 95% CI 1.35 to 2.30; Analysis
2.1). Notably, during subgroup analysis, the effect size appeared to
increase as the daily dose of pregabalin increased. Neither dose of
controlled-release pregabalin, 165 mg/d or 330 mg/d, was associ-
ated with a significantly higher proportion of participants achiev-
ing a 50% or greater reduction in seizure frequency than placebo
(165 mg/d: RR 1.03, 95% CI 0.72 to 1.48; 330 mg: RR 1.26,
95% CI 0.91 to 1.75; Analysis 2.1). Although the effect size did
vary between subgroups, the direction of the effect (pregabalin
being advantageous compared to placebo) was consistent amongst
all subgroups, even those showing the smallest and statistically in-
significant risk ratios.
Best-case and worst-case analyses
A best-case analysis (all treatment withdrawals in the treatment
group assumed to be responders), pooling all doses (50 mg to
600 mg/day immediate- and controlled-release pregabalin), again
showed that participants allocated to pregabalin were significantly
more likely to achieve a 50% or greater reduction in seizure fre-
quency compared to placebo (RR 3.57, 95% CI 2.17 to 5.86;
Analysis 1.2). Again, we detected significant heterogeneity within
the data set (I2 = 88%) and so employed a random-effects model
followed by a subgroup analysis according to dose to investigate
dose as a potential source of heterogeneity (Analysis 2.2). Subgroup
analyses assessing the effect of individual doses showed significant
effects for all pregabalin doses, including 330 mg/d controlled-
release pregabalin (50 mg/d: RR 1.87, 95% CI 1.03 to 3.40; 150
mg/d: RR 3.18, 95% CI 2.00 to 5.06; 300 mg/d: RR 4.37, 95%
CI 2.61 to 7.29; 600 mg/d: RR 7.72, 95% CI 5.64 to 10.57;
titrated 150 mg/d to 600 mg/d: RR 2.86, 95% CI 2.24 to 3.65;
330 mg/d controlled-release: RR 1.63, 95% CI 1.21 to 2.20),
with the exception of 165 mg/d controlled-release pregabalin (RR
1.28, 95% CI 0.92 to 1.79), for which the effect size remained
insignificant, even during best-case analysis (Analysis 2.2).
In contrast, a worst-case analysis (all dropouts from the control
group assumed to be responders) pooling all doses of pregabalin
(50 mg/d to 600 mg/d and including controlled-release prega-
balin) showed no significant difference between pregabalin and
placebo for the outcome 50% or greater seizure reduction (RR
1.15, 95% CI 0.92 to 1.43; Analysis 1.3). The analysis did, how-
ever, continue to show significant heterogeneity within the data set
(I2 = 66%). Subgroup analyses by dose indicated that one dose (50
mg/d) was associated with significantly fewer participants achiev-
ing a 50% or greater seizure reduction in the pregabalin group
compared to the placebo group during worst-case analysis (RR
0.55, 95% CI 0.30 to 0.99). In contrast, 600 mg/d pregabalin
continued to demonstrate a significant advantage over placebo
with respect to the number of participants who achieved a 50%
or greater reduction in seizure frequency (RR 1.72, 95% CI 1.42
to 2.09). There were no significant differences between the other
pregabalin dose groups and placebo for the outcome during worst-
case analysis (150 mg/d: RR 0.96, 95% CI 0.66 to 1.38; 300 mg/
d: RR 1.48, 95% CI 0.98 to 2.23; titrated 150 mg/d to 600 mg/
d: RR 0.92, 95% CI 0.76 to 1.12; 165 mg/d controlled-release:
RR 0.79, 95% CI 0.57 to 1.09; 330 mg/d controlled-release: RR
0.96, 95% CI 0.72 to 1.28; Analysis 2.3).
Dose regression analysis for 50% response
We fitted a generalised linear mixed model to the data from
Analysis 2.1 (Figure 5) to estimate the effect of dose on the primary
outcome, 50% or greater reduction in seizure frequency (details
in Data synthesis). This method estimates an odds ratio (OR) as
opposed to an RR.Dose was standardised by its standard deviation
(245 mg). The odds of response (50% reduction in seizure fre-
quency) approximately doubled (OR 1.99, 95% CI 1.74 to 2.28)
with estimated between-study standard deviation of 0.17 (stan-
dard error 0.13) for each 245 mg increase in dose of pregabalin.
This translates into an estimated doubling of odds of response
with an increase in dose of 245 mg (e.g. a doubling of odds from
approximately 300 mg to 600 mg).
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Figure 5. Forest plot of comparison: 1 Pregabalin versus placebo: 50% seizure reduction - intention-to-treat
analysis, outcome: 2.1 50% or greater reduction in seizure frequency, intention-to-treat.
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Seizure freedom
Four included studies involving a total of 1125 participants re-
ported seizure freedom (Baulac 2010; Beydoun 2005; Elger 2005;
Lee 2009). Specifically, these studies reported the number of par-
ticipants who had complete cessation of their seizures over the
entire treatment period. In contrast, the study by Arroyo 2004
recorded the number of participants who were seizure-free during
the last 28 days of their treatment. This definition of seizure free-
domwas not consistent with the definition used by the other stud-
ies, therefore we excluded the data extracted from Arroyo 2004
from the analysis.
The pooled analysis, consisting of all doses, showed evidence of
no heterogeneity (I2 = 11%), therefore we continued to employ a
fixed-effect model. The analysis demonstrated that participants al-
located to pregabalinwere significantlymore likely to attain seizure
freedom than those allocated to placebo (RR 3.94, 95% CI 1.50
to 10.37; Analysis 1.4).
Although we detected no important heterogeneity, we continued
to use subgroup analysis to investigate whether there was any po-
tentially undetected heterogeneity due to experimental dose of
pregabalin. Two subgroups were included in the analysis, 600 mg/
d pregabalin and 150 mg/d to 600 mg/d titrated dose of prega-
balin. Subgroup analysis highlighted that a significantly greater
number of participants randomised to 600 mg/d pregabalin at-
tained seizure freedom compared to those randomised to placebo
(RR 6.92, 95% CI 1.31 to 36.70; Analysis 2.4). There was no sig-
nificant difference in the proportion of participants who achieved
seizure freedom between participants allocated to 150 mg/d to
600 mg/d titrated dose of pregabalin compared to placebo (RR
2.39, 95% CI 0.83 to 6.89; Analysis 2.4).
Treatment withdrawal for any reason
An analysis pooling all doses (50 mg/d to 600 mg/d immediate-
and controlled-release pregabalin) showed no evidence of hetero-
geneity (I2 = 0%), therefore we used a fixed-effect model. Partici-
pants allocated to pregabalin were significantly more likely to have
withdrawn from treatment compared to those allocated to placebo
(RR 1.35, 95% CI 1.11 to 1.65; Analysis 1.5). Subgroup analysis
assessing the individual doses showed no significant effect for 50
mg/d (RR 0.87, 95% CI 0.40 to 1.89); 150 mg/d (RR 0.72, 95%
CI 0.41 to 1.28); 300 mg/d (RR 1.62, 95% CI 0.85 to 3.10);
or 150 mg/d to 600 mg/d titrated dose of immediate-release pre-
gabalin (RR 1.20, 95% CI 0.89 to 1.62) compared to placebo.
Similarly, neither dose of controlled-release pregabalin displayed
a significant effect on the rate of treatment withdrawal (165 mg/
d controlled-release: RR 0.82, 95% CI 0.36 to 1.86; 330 mg/
d controlled-release: RR 1.21, 95% CI 0.59 to 2.46). The only
dose of pregabalin associated with a significantly higher treatment
withdrawal rate for any reason compared to placebo was 600 mg/
d (RR 1.84, 95% CI 1.42 to 2.40; Analysis 2.5). In fact, the two
lowest doses of immediate-release pregabalin (50 mg/d and 150
mg/d) and lowest dose of controlled-release pregabalin (165 mg/
d) both actually estimated risk ratios of less than one (50 mg/d:
RR 0.87, 95% CI 0.40 to 1.89; 150 mg/d: RR 0.72, 95% CI 0.41
to 1.28; 165 mg/d controlled-release: RR 0.82, 95% CI 0.36 to
1.86), meaning that fewer people randomised to low doses of pre-
gabalin withdrew from treatment compared to those randomised
to placebo.
Treatment withdrawal due to adverse effects
An analysis pooling all doses (50 mg/d to 600 mg/d immediate-
and controlled-release pregabalin) showed no evidence of hetero-
geneity (I2 = 0%), thus we used a fixed-effect model for the anal-
ysis. Participants allocated to pregabalin were significantly more
likely to withdraw from treatment due to adverse effects (RR 2.65,
95% CI 1.88 to 3.74; Analysis 1.6). Subgroup analyses assessing
treatment withdrawal with differing doses suggested that a higher
withdrawal rate was associated with higher doses of pregabalin (50
mg/d: RR 1.36, 95% CI 0.43 to 4.31; 150 mg/d: RR 1.02, 95%
CI 0.45 to 2.32; 300 mg/d: RR 2.89, 95% CI 1.07 to 7.78; 600
mg/d: RR 3.78, 95% CI 2.47 to 5.81; Analysis 2.6). Specifically,
participants randomised to 300mg/d, 600 mg/d, or a titrated dose
of pregabalin of 150 mg/d to 600 mg/d (RR 2.26, 95% CI 1.30
to 3.95) were all significantly more likely to withdraw from treat-
ment due to adverse effects than were participants randomised to
placebo. Neither dose of controlled-release pregabalin was associ-
ated with a significantly different treatment withdrawal rate due to
adverse effects compared to placebo (165 mg/d controlled-release:
RR 1.09, 95% CI 0.22 to 5.27; 330 mg/d controlled-release: RR
2.57, 95% CI 0.70 to 9.45).
Adverse effects
In addition to the five prespecified adverse effects, weight gain
and headache were amongst the most common adverse effects re-
ported. Analyses pooling across doses (50 mg/d to 600 mg/d im-
mediate- and controlled-release pregabalin) indicated that ataxia
(RR 3.90, 99%CI 2.05 to 7.42; Analysis 1.7); dizziness (RR 3.15,
99% CI 2.23 to 4.44; Analysis 1.8); fatigue (RR 1.34, 99% CI
0.93 to 1.94; Analysis 1.9); somnolence (RR 2.15, 99% CI 1.50
to 3.09; Analysis 1.12); and weight gain (RR 5.02, 99% CI 2.49
to 10.10; Analysis 1.13) were all significantly more prevalent in
participants randomised to pregabalin compared to placebo. Nau-
sea incidence did not differ significantly between pregabalin and
placebo groups (RR 1.20, 99% CI 0.56 to 2.58; Analysis 1.11). In
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contrast, participants randomised to pregabalin were significantly
less likely to experience headache compared to those randomised
to placebo (RR 0.63, 99% CI 0.42 to 0.93; Analysis 1.10). We
detected no significant heterogeneity for any of the adverse effects
analysed (all: I2 = 0%).
Subgroup analysis according to dose of pregabalin revealed that
the highest dose, 600 mg/d pregabalin, was consistently associated
with a significantly greater likelihood of participants experiencing
adverse effects compared to placebo. Specifically, participants re-
ceiving 600 mg/d were more likely to experience the following ad-
verse effects than participants receiving placebo: ataxia (RR 4.49,
99% CI 2.25 to 8.95; Analysis 2.7); dizziness (RR 3.72, 99% CI
2.42 to 5.69; Analysis 2.8); somnolence (RR 2.57, 99% CI 1.64
to 4.03; Analysis 2.12); and weight gain (RR 5.88, 99% CI 2.52
to 13.73; Analysis 2.13). Similarly, a titrated dose of 150 mg/d to
600 mg/d pregabalin was associated with a significantly increased
incidence rate of ataxia (RR 4.46, 99% CI 1.28 to 15.48; Analysis
2.7); dizziness (RR 3.08, 99% CI 1.80 to 5.28; Analysis 2.8);
somnolence (RR 2.35, 99% CI 1.31 to 4.19; Analysis 2.12); and
weight gain (RR 3.64, 99% CI 1.49 to 8.87; Analysis 2.13). In
contrast, none of the other dose subgroups were consistently as-
sociated with an increased likelihood of the individual adverse ef-
fects. Interestingly, all of the dose groups, with the exception of 50
mg/d pregabalin (RR 1.01, 99% CI 0.31 to 3.33), were, however,
associated with the an increased incidence of dizziness compared
to placebo (Analysis 2.8). Furthermore, all of the dose subgroups
had a risk ratio suggesting that there was a decreased likelihood
of participants experiencing headache when receiving pregabalin
compared to those receiving placebo, however the difference was
only significant for one subgroup, 150 mg/d pregabalin (RR 0.53,
99% CI 0.24 to 1.17; Analysis 2.10).
Pregabalin versus active comparator
Three included studies involving a total of 1286 participants com-
pared pregabalin to other existing AEDs as active comparators.
One study included 293 randomised participants and compared
pregabalin with lamotrigine as the active control drug (Baulac
2010). Another trial included 509 randomised participants and
compared pregabalin with levetiracetam as the active control drug
(Zaccara 2014). The remaining study, French 2016, involved 484
participants and compared pregabalin with gabapentin as the ac-
tive control drug.
50% or greater reduction in seizure frequency
All three included studies (1286 participants) reported this out-
come.We detected significant heterogeneity within the data set (I2
= 61%), therefore we used a random-effects model. The likelihood
of participants achieving a 50% or greater reduction in seizure
frequency was not significantly different based on whether partici-
pants were randomised to pregabalin or an alternative active-com-
parator AED (RR 1.03, 95% CI 0.85 to 1.25; Analysis 3.1). Inter-
estingly, subgroup analysis according to active-comparator control
group revealed that participants receiving pregabalin were signifi-
cantly more likely to achieve a 50% or greater reduction in seizure
frequency compared to those receiving the active comparator lam-
otrigine (RR 1.47, 95% CI 1.03 to 2.12; Analysis 4.1), however
there was no significant difference between pregabalin and either
levetiracetam (RR 0.94, 95% CI 0.80 to 1.11) or gabapentin (RR
0.96, 95% CI 0.82 to 1.12). The test for subgroup differences
did not highlight a significant subgroup effect (P = 0.07; Analysis
4.1).
Best-case and worst-case analyses
We subsequently conducted a best-case analysis (all dropouts as-
sumed to be responders to treatment). This revealed a significant
increase in the proportion of participants who achieved a 50% or
greater seizure reduction in favour of the pregabalin group com-
pared to active comparators (RR 1.60, 95% CI 1.17 to 2.19;
Analysis 3.2).However, aworst-case analysis (all dropouts assumed
to be responders to control) revealed a significant increase in the
proportion of participants who achieved a 50% or greater seizure
reduction in favour of the control group (RR 0.67, 95% CI 0.62
to 0.74; Analysis 3.3).
This was similarly the case when best-case and worst-case analysis
was performed for each of the individual active comparators dur-
ing subgroup analysis. Pregabalin appeared to be more efficacious
than lamotrigine (RR 2.73, 95% CI 1.99 to 3.74); levetiracetam
(RR 1.27, 95% CI 1.11 to 1.46); and gabapentin (RR 1.34, 95%
CI 1.18 to 1.52) during best-case analysis (Analysis 4.2), but was
shown to perform significantly worse than the active compara-
tors during worst-case analysis (pregabalin versus lamotrigine: RR
0.68, 95% CI 0.52 to 0.88; pregabalin versus levetiracetam: RR
0.71, 95% CI 0.62 to 0.82; pregabalin versus gabapentin: RR
0.64, 95% CI 0.57 to 0.73; Analysis 4.3). The test for subgroup
differences detected significantly different effect sizes between the
subgroups during best-case scenario analysis (P < 0.001; Analysis
4.2), but not during worst-case analysis (P = 0.57; Analysis 4.3).
Seizure freedom
Only two included studies involving a total of 802 participants
reported this outcome (Baulac 2010; Zaccara 2014). French 2016
reported no data regarding seizure freedom for this comparison.
Participants randomised to pregabalin were significantly less likely
to attain seizure freedom than participants randomised to an ac-
tive comparator (RR 0.59, 95% CI 0.37 to 0.95; Analysis 3.4).
When analysed separately during subgroup analysis according to
active-comparator control group , the proportion of participants
attaining seizure freedom was not significantly different for those
receiving pregabalin compared to those receiving the active com-
parator lamotrigine (RR 1.39, 95%CI 0.40 to 4.83; Analysis 4.4).
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However, the seizure freedom rate was significantly lower in par-
ticipants receiving pregabalin than in those receiving levetiracetam
(RR 0.50, 95% CI 0.30 to 0.85; Analysis 4.4). Despite this, the
test for subgroup differences did not reveal any significant differ-
ences between the effect size estimated by the two active-compara-
tor control groups (P = 0.14; Analysis 4.4).
Treatment withdrawal for any reason
Three included studies involving a total of 1286 randomised
participants reported this outcome (Baulac 2010; French 2016;
Zaccara 2014). We found no significant difference in the rate of
treatment withdrawal for any reason between pregabalin and ac-
tive comparators (RR 0.93, 95% CI 0.76 to 1.13; Analysis 3.5).
Similarly, during subgroup analysis according to active compara-
tor, pregabalin was not shown to have a significantly different
rate of treatment withdrawal for any reason compared to any of
the individual active comparators: lamotrigine (RR 1.07, 95% CI
0.75 to 1.52); levetiracetam (RR 1.03, 95% CI 0.71 to 1.49);
and gabapentin (RR 0.78, 95% CI 0.57 to 1.07) (Analysis 4.5).
Furthermore, the test for subgroup differences was not statistically
significant (P = 0.36).
Treatment withdrawal due to adverse effects
Three included studies involving a total of 1286 randomised par-
ticipants also reported treatment withdrawal due specifically to
adverse effects experienced (Baulac 2010; French 2016; Zaccara
2014). Again, there was no significant difference in the propor-
tion of participants who withdrew from treatment due to adverse
effects between those randomised to pregabalin compared to an
active comparator (RR 1.04, 95% CI 0.73 to 1.48; Analysis 3.6).
According to the subgroup analysis, pregabalin did not demon-
strate a significantly different treatment withdrawal rate due to
adverse effects compared to any of the individual active compara-
tors: lamotrigine (RR 0.89, 95% CI 0.53 to 1.48); levetiracetam
(RR 1.29, 95% CI 0.66 to 2.54); or gabapentin (RR 1.07, 95%
CI 0.54 to 2.11) (Analysis 4.6). Again, the test for subgroup dif-
ference was statistically insignificant (P = 0.69).
Adverse effects
Although the three included studies involving a total of 1286
participants documented and reported adverse effects, they did not
report all of the adverse effects we were investigating in this review
(Baulac 2010; French 2016; Zaccara 2014). Notably, for some
adverse effects, data were only supplied by one study, namely for
ataxia, fatigue, and nausea. Furthermore, we detected significant
heterogeneity within the data sets for the following adverse effects:
dizziness (I2 = 65%), headache (I2 = 64%), and weight gain (I2 =
60%). We therefore used a random-effects model for the analysis
of these adverse effects.
More participants randomised to pregabalin compared to those
randomised to active comparators experienced dizziness (RR 1.64,
99% CI 0.85 to 3.16; Analysis 3.8) and weight gain (RR 2.87,
99% CI 0.94 to 8.75; Analysis 3.13). In contrast, significantly
fewer participants randomised to pregabalin compared to those
randomised to active comparators experienced nausea (RR 0.20,
99% CI 0.04 to 1.01; Analysis 3.11). Importantly, however, only
one study, Zaccara 2014, provided data for this outcome, so it is
difficult to draw any conclusions from this result. The occurrence
of ataxia (RR 1.72, 99% CI 0.54 to 5.55; Analysis 3.7); fatigue
(RR 1.72, 99%CI 0.77 to 3.83; Analysis 3.9); headache (RR 0.83,
99% CI 0.41 to 1.65; Analysis 3.10); and somnolence (RR 1.16,
99% CI 0.88 to 1.53; Analysis 3.12) did not differ significantly
between pregabalin and active-comparator treatment groups.
Subgroup analysis according to active-comparator control group
revealed that pregabalin was associated with a higher incidence
rate for some of the adverse effects investigated compared to two
of the active-comparator controls, lamotrigine and levetiracetam.
Specifically, participants receivingpregabalinweremore likely than
those receiving the active comparator lamotrigine to experience
the following adverse effects: dizziness (RR 2.94, 99% CI 1.32
to 6.52; Analysis 4.7); somnolence (RR 1.99, 99% CI 0.91 to
4.33; Analysis 4.10); and weight gain (RR 4.33, 99% CI 0.86 to
21.68; Analysis 4.11). Similarly, participants receiving pregabalin
were more likely than those receiving the active comparator leve-
tiracetam to experience dizziness (RR 1.44, 99% CI 0.89 to 2.34;
Analysis 4.7) and weight gain (RR 4.82, 99% CI 1.39 to 16.74;
Analysis 4.11). Interestingly, the incidence rate of adverse effects
for pregabalin and gabapentin was not significantly different. No-
tably, however, pregabalin was associated with a significantly lower
rate of headache compared to lamotrigine (RR 0.52, 99% CI 0.26
to 1.05; Analysis 4.8), as well as a significantly lower rate of nau-
sea compared to levetiracetam (RR 0.20, 99% CI 0.04 to 1.01;
Analysis 4.9), as alluded to earlier. Importantly, only one study
provided data to each of the subgroups included in the subgroup
analysis. Interestingly, the test for subgroup differences for each of
the individual adverse effects indicated that there was not a sig-
nificant subgroup effect dependent on active-comparator control
(dizziness: P = 0.06; headache: P = 0.06; somnolence: P = 0.15;
weight gain: P = 0.08).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Pregabalin compared to active comparator for drug- resistant focal epilepsy
Patient or population: drug-resistant focal epilepsy
Setting: outpaitent sett ing
Intervention: pregabalin
Comparison: act ive comparator (gabapent in, lamotrigine and levet iracetam)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with active com-
parator
Risk with Pregabalin
50% or greater reduc-
tion in seizure fre-
quency
Follow-up: range 16 to
21 weeks
Study population RR 1.03
(0.85 to 1.25)
1286
(3 RCTs)
⊕⊕©©
LOW 12
According to ITT anal-
ysis, pregabalin does
not appear to af fect
the proport ion of peo-
ple achieving a 50%
or greater reduct ion in
seizure f requency com-
pared to other ac-
t ive comparators. We
are, however, uncertain
about this f inding
491 per 1,000 505 per 1,000
(417 to 613)
50% or greater reduc-
tion in seizure fre-
quency - best-case
analysis
Follow-up: range 16 to
21 weeks
Study population RR 1.60
(1.17 to 2.19)
1286
(3 RCTs)
⊕©©©
VERY LOW 13
According to best-
case analysis, prega-
balin may increase the
proport ion of part ici-
pants achieving a 50%
or greater reduct ion in
seizure f requency, how-
ever, we are very uncer-
tain about this f inding
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491 per 1,000 785 per 1,000
(574 to 1,000)
50% or greater reduc-
tion in seizure fre-
quency - worst-case
analysis
Follow-up: range 16 to
21 weeks
Study population RR 0.67
(0.62 to 0.74)
1286
(3 RCTs)
⊕⊕⊕©
MODERATE 1
According to worst-
case analysis, prega-
balin may decrease the
proport ion of part ici-
pants achieving a 50%
or greater reduct ion in
seizure f requency. We
are moderately certain
about this f inding
732 per 1,000 490 per 1,000
(454 to 542)
Seizure freedom
Follow-up: range 16 to
17 weeks
Study population RR 0.59
(0.37 to 0.95)
802
(2 RCTs)
⊕©©©
VERY LOW 14
Pregabalin may reduce
the number of people
achieving seizure f ree-
dom, but we are very
uncertain
106 per 1,000 63 per 1,000
(39 to 101)
Treatment withdrawal
for any reason
Follow-up: range 16 to
21 weeks
Study population RR 0.93
(0.76 to 1.13)
1286
(3 RCTs)
⊕⊕©©
LOW 15
Pregabalin does not ap-
pear to af fect the num-
ber of part icipants with-
drawing f rom treatment
for any reason, how-
ever, we are uncertain
241 per 1,000 224 per 1,000
(183 to 273)
Treatment withdrawal
for adverse events
Follow-up: range 16 to
21 weeks
Study population RR 1.04
(0.73 to 1.48)
1286
(3 RCTs)
⊕⊕©©
LOW 15
Pregabalin does not ap-
pear to af fect the num-
ber of part icipants with-
drawing f rom treatment
for adverse ef fects, but
we are uncertain
85 per 1,000 88 per 1,000
(62 to 125)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; ITT: intent ion-to-treat; RCT: randomised controlled trial; RR: Risk rat io
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GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded once for risk of bias: one study did not conf irm the method of randomisat ion; all studies failed to specif y their
method of allocat ion concealment; one study did not provide information on the method of blinding.
2 Downgraded once for inconsistency: signif icant heterogeneity (P < 0.10) was detected within the data set.
3 Downgraded twice for inconsistency: very signif icant heterogeneity (P < 0.05) was detected within the data set.
4 Downgraded twice for imprecision: very low number of events (< 100) which did not suf f ice the opt imal information size.
5 Downgraded once for imprecision: very low number of events (< 400) which did not suf f ice the opt imal information size.
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D I S C U S S I O N
Summary of main results
We identified six randomised placebo-controlled parallel trials
(Arroyo 2004; Beydoun 2005; Elger 2005; French 2003; French
2014; Lee 2009), two active-comparator-controlled parallel trials
(French 2016; Zaccara 2014), and one trial that included both
an active-drug group and a placebo control group (Baulac 2010).
All nine studies were industry-sponsored (Pfizer Ltd). Summary
trial data were taken from the relevant publications, and individ-
ual patient data were not obtained. We attempted to retrieve the
respective trial protocols but were unsuccessful. All studies ap-
peared to be of good methodological quality overall. Most were
randomised using suitable sequence generation methods, however
none of the studies reported their methods for concealing alloca-
tion. All included studies were reported to be double-blind, but
only six studies provided adequate details of how blinding was
achieved and maintained. Few participants were lost to follow-
up, however overall attrition rates were high for certain studies,
especially those that included higher doses of pregabalin.
The included studies tested doses of pregabalin ranging from 50
mg/d to 600 mg/d, including both immediate- and controlled-
release pregabalin. The results showed that pregabalin, when used
as an add-on treatment, can reduce seizure frequency in individuals
with drug-resistant focal epilepsy. In the main analysis, when all
doses of pregabalin were pooled, the RR for a 50% or greater
reduction in seizure frequency was 2.28 (95% CI 1.52 to 3.42),
thus demonstrating that out of 100 people with refractory epilepsy,
42 are likely to have their seizures reduced when taking pregabalin,
compared to 18 out of 100 people taking placebo. A summary of
the main findings for the pooled analysis of all doses of pregabalin
versus placebo can be found in the Summary of findings for the
main comparison.
We detected significant heterogeneity within the data set for the
outcome 50% or greater reduction in seizure frequency. Whilst
all doses of immediate-release pregabalin above 50 mg/d were ob-
served to significantly increase 50% responder rate (the proportion
of participants achieving 50% or greater seizure reduction) during
ITT analysis, only 600 mg/d pregabalin consistently showed a sig-
nificant therapeutic effect compared to placebo during ITT, best-
case, and worst-case analysis. This suggests that the effect noted at
600 mg/d is a true effect, whereas it is possible that the therapeutic
effect reported at the lower doses of pregabalin could be as a result
of treatment withdrawals and may, therefore, not be accurate of
the true efficacy of pregabalin. Furthermore, the significant ther-
apeutic effect (an increased proportion of participants achieving
50% or greater seizure reduction) observed during pooled analy-
sis was not consistently detected. Specifically, it was not reported
during worst-case analysis. This raises doubts about the validity
of the pooled effect described, and suggests that the therapeutic
effect may be dose-dependent and might only be observed at the
higher doses of pregabalin, rather than being a feature of all doses
of pregabalin, generally.
The alternative efficacy outcome, seizure freedom, again empha-
sised the therapeutic potential of pregabalin. Participants allocated
to pregabalin were significantly more likely to attain seizure free-
dom. However, data for this outcome were only provided by four
studies, which accounted for two subgroups, 600 mg/d pregabalin
and titrated dose of 150 mg/d to 600 mg/d. Consequently, we
have no data specifically for the lower doses of pregabalin that
were included in the previous efficacy analyses for 50% or greater
seizure reduction. This potentially explains the lack of heterogene-
ity present in the seizure freedom data set compared to that re-
vealed for the primary efficacy outcome. Again, the subgroup anal-
ysis indicated a high risk ratio for 600 mg/d (RR 6.92, 95% CI
1.31 to 36.70), emphasising a large treatment effect at this dose.
In this scenario, it is estimated that if 1000 people were to receive
pregabalin, 41 would likely achieve complete cessation of seizures,
compared to 6 people if 1000 people were to receive placebo. No-
tably, other than 50% or greater reduction in seizure frequency,
none of the other outcomes for the comparison pregabalin versus
placebo displayed significant heterogeneity.
Although both efficacy outcomes recognised 600 mg/d pregabalin
as a highly efficacious dose, it is important to acknowledge that
600 mg/d pregabalin was also associated with tolerability issues.
This was the only dose to display a significantly higher withdrawal
rate for any reason compared to placebo during subgroup analysis,
and was one of only three doses to display a significantly higher
treatment withdrawal rate due specifically to adverse effects. No-
tably, 600 mg/d pregabalin demonstrated the greatest risk ratio
(RR 3.78, 95% CI 2.47 to 5.81) for treatment withdrawal due
to adverse effects, indicating a very large effect size. Accordingly,
600 mg/d pregabalin was repeatedly associated with an increased
incidence rate for the majority of the adverse effects investigated,
namely ataxia, dizziness, fatigue, somnolence, and weight gain.
When pregabalin was compared to other AEDs, rather than
placebo, it did not show a significant therapeutic advantage with
regard to 50% responder rate during pooled analysis. During sub-
group analysis, however, pregabalin was associated with a signif-
icantly higher responder rate compared to lamotrigine, but not
when compared to levetiracetam or gabapentin. Surprisingly, the
pooled analysis for the alternative efficacy outcome showed that
participants randomised to pregabalin were significantly less likely
to attain seizure freedom. Although we did not detect statistical
heterogeneity in the data set, the two studies (each contributing to
one subgroup) indicated opposing effects. The study comparing
pregabalin to lamotrigine estimated an insignificant therapeutic
effect (RR 1.39, 95% CI 0.40 to 4.83), whereas the study com-
paring pregabalin to levetiracetam indicated a diminished seixure
freedom rate for participants randomised to pregabalin (RR 0.50,
95% CI 0.30 to 0.85). We detected no significant differences in
treatment withdrawal rate for any reason or due to adverse effects,
specifically, during either pooled analysis or subgroup analysis.
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The majority of the adverse effects investigated, namely ataxia, fa-
tigue, headache, and somnolence, were no more prevalent in par-
ticipants randomised to pregabalin than in those randomised to
active control. Participants receiving pregabalin did appear to be
much more likely to experience weight gain compared to partici-
pants receiving active control. Specifically, during subgroup anal-
ysis large effect sizes were recognised for pregabalin versus both
lamotrigine and levetiracetam. Notably, however, subgroup anal-
ysis did not reveal any differences in incidence rates of individual
adverse effects between pregabalin and gabapentin. This is not sur-
prising given that pregabalin and gabapentin are structurally re-
lated. Both drugs are structural analogues of γ -aminobutyric acid
(GABA) and both bind with high affinity to the α-2-δ subunit of
voltage-gated calcium channels (Bockbrader 2010).
Overall completeness and applicability of
evidence
Heterogeneity was a serious issue for the outcome 50% or greater
reduction in seizure frequency for both comparisons, pregabalin
versus placebo and pregabalin versus active comparator. As a result,
the treatment effect described and estimated for each pooled anal-
ysis may only be minimally informative. For the comparison pre-
gabalin versus placebo, a large range of doses, including a titrated
dose regimen, were combined into a single meta-analysis. It is less
clear what dose individual participants were actually receiving dur-
ing a titrated dose regimen. Data for many of these participants
could have likely been entered into specific dose subgroups (i.e.
150 mg/d, 300 mg/d, or 600 mg/d), if the stratified data to en-
able this had been available in the relevant trial publications. This
further complicates the meta-analysis.
Additionally, the pooled analysis for the comparison pregabalin
versus placebo included both immediate-release and controlled-re-
lease pregabalin, which have very different pharmacokinetics. This
explains the difference in effect size calculated and the apparent
heterogeneity between subgroups. For the other comparison, pre-
gabalin versus active comparator, it is possible that the other AEDs
equally have very different mechanisms of actions and potencies,
therefore, it is difficult to combine them into a meta-analysis. As
a result, for both comparisons, the pooled effect is unlikely to be
representative of what will occur at every dose of pregabalin, or to
reflect what the anticipated effect size of pregabalin is compared
to another AED.
For this reason, the effect sizes reported from the subgroup analyses
should be consideredmore informative than the effect size reported
from the pooled analysis for the outcome 50% or greater reduc-
tion in seizure frequency. The variation in the effect reported thus
limits our ability to sufficiently answer the question of whether
pregabalin is more efficacious than placebo when used as an add-
on treatment for drug-resistant focal epilepsy. The overall consen-
sus appears to be that higher doses of immediate-release prega-
balin, specifically 150 mg/d and greater, are more efficacious than
placebo with regard to the 50% responder rate, however, prega-
balin does not appear to offer a competitive advantage over other
AEDs.
With further regard to subgroup analysis, it is important to recog-
nise that for each active-comparator subgroup (i.e. pregabalin
versus lamotrigine, pregabalin versus levetiracetam, and prega-
balin versus gabapentin) for the comparison pregabalin versus ac-
tive comparator, data were only supplied by one study, therefore
were very limited. Similarly, for the comparison pregabalin ver-
sus placebo, data were only provided by one study for four of the
subgroups: 50 mg/d, 300 mg/d, 165 mg/d controlled-release, and
330 mg/d controlled-release pregabalin. As a result, multiple sub-
groups may have been underpowered and therefore any conclu-
sions reached must be interpreted cautiously.
An additional issue is that the data included in this review were
mainly derived from adult study populations (patients aged 16
years and above). Only one study included a subset of younger pa-
tients (French 2003). Their inclusion criteria specified that people
aged 12 and above were eligible for the study. As a result, teenagers
were included in the study, however children remained excluded.
Consequently, the findings reported in this review are only appli-
cable to adults and are not informative of the effects of pregabalin
in children.
Quality of the evidence
We assessed the certainty of the evidence for the primary and
secondary outcomes for the comparison pregabalin versus placebo
using theGRADEapproach.TheGRADEassessment is presented
and summarised in Summary of findings for themain comparison.
Overall, we rated the evidence as very low tomoderate in certainty.
We downgraded all outcomes once due to the unclear risk of bias
across studies, mainly because all of the included studies failed
to describe how allocation was concealed. Three of these studies
also did not provide details about either the generation of the
randomisation sequence or how blinding was effectively achieved.
We further downgraded the certainty of evidence for all three
analyses, ITT, best-case, and worst-case analysis, for the outcome
50%or greater reduction in seizure frequency due to the significant
statistical heterogeneity detected. As explained above, statistical
heterogeneity greatly affected our ability to answer our hypothesis
and impacted the validity of our conclusion. Furthermore, the
ITT and best-case analyses had to been downgraded once more
because we strongly suspected publication bias, as demonstrated
by the funnel plot generated (Figure 6). It is clear from the funnel
plot that the larger studies are predicting a much smaller effect size
than the smaller studies. Ideally, we would expect the data points
to produce a funnel shape, with the risk ratios estimated by the
individual studies evenly distributed either side of the estimated
pooled effect. Instead, the data points plotted from the individual
study effects look more similar to a linear regression, suggesting
publication bias.
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Figure 6. Funnel plot of comparison: 1 Pregabalin versus placebo, outcome: 1.1 50% or greater reduction in
seizure frequency - intention-to-treat analysis.
Both outcomes concerning treatment withdrawal and the other
efficacy outcome, seizure freedom, were not affected by either het-
erogeneity or suspected publication bias. Both seizure freedom
and treatment withdrawal due to adverse effects were, however,
rarer events compared to the outcome 50% or greater reduction
in seizure frequency, and therefore, the number of events reported
did not satisfy the optimal information size necessary for a robust
meta-analysis. As a consequence, we downgraded the certainty of
the evidence to low. Nevertheless, we were able to then upgrade
the certainty of the evidence back to moderate for the outcomes
seizure freedom and treatment withdrawal due to adverse effects
because of the large effect size noted for each (RR > 2.00). We
also upgraded the certainty of the evidence for the outcome 50%
or greater reduction in seizure frequency for both the ITT and
best-case analysis, under the same principle. We further upgraded
the certainty of the evidence for the ITT analysis as a result of
the dose-response relationship detected by the regression analysis.
This produced an overall judgement of low certainty of evidence
for the primary efficacy outcome.
The low certainty of evidence for the outcome 50% or greater re-
duction in seizure frequency means that we are uncertain whether
the effect size estimated is accurate of the true efficacy of prega-
balin. In contrast, the rating of moderate certainty of evidence for
the other three outcomes, seizure freedom and treatment with-
drawal for any reason and due to adverse effects, means that we are
fairly certain that the effect size reported is an accurate estimate of
the true effect size.
Potential biases in the review process
The approach to analysis for all of the included trials used the
’last observation carried forward’ method. For participants failing
to complete follow-up, seizure frequency data were extrapolated
to the whole treatment period, whereas for participants with no
seizure data during the treatment period, baseline data were ex-
trapolated. Whilst this approach may help minimise bias due to
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losses to follow-up (and is preferred by drug regulatory authori-
ties), its use must be taken into consideration when interpreting
the results of this systematic review, especially due to the high at-
trition rate noted in certain studies.
Importantly, the ’last observation carried forward’method assumes
that a participant’s response does not alter after treatment with-
drawal. Specifically, themethod does not consider any fluctuations
in a participant’s response or incorporate any imputation uncer-
tainty. Consequently, the method likely predicts narrower confi-
dence intervals than would normally be observed and, as a result,
the effect size estimate is more likely to be statistically significant.
Care must therefore be taken when considering the significance of
the results presented.
Agreements and disagreements with other
studies or reviews
We were able to identify two other systematic reviews that in-
vestigated pregabalin as an add-on therapy for drug-resistant fo-
cal epilepsy. Neither review included a meta-analysis, but both
emphasised the therapeutic potential of pregabalin compared to
placebo. Specifically, both reviews reported the outcome 50% or
greater reduction in seizure frequency as evidence of pregabalin’s
antiepileptic effect. One review reported a responder rate (the pro-
portion of participants achieving a 50% or greater reduction in
seizure frequency) of 31% to 51% (Hamandi 2006), whilst the
other reported a responder rate of 14% to 51% (Ryvlin 2008).
Notably, both reviews collected data from studies included in this
review, namely Arroyo 2004, Beydoun 2005, Elger 2005, and
French 2003. Although both studies are in overall agreement with
our current review, our current review provides novel information
compared to the currently available reviews due to the meta-anal-
ysis conducted and the additional studies included.
The latter review by Ryvlin 2008 also discussed the long-term ef-
fectiveness of pregabalin after reviewing data collected from four
open-label extension studies. Collectively, the data suggested that
there was no loss of efficacy with the long-term use of pregabalin.
For patients who entered long-term extension studies, 3.7% of
patients remained seizure-free during the last year of the respective
studies. Likewise, a long-term observational study that followed
105 patients (aged 16 to 81 years) over a one-year period revealed
that 5.7% of patients reported that they had been seizure-free for
the previous 4 weeks when contacted at 12 months, and 17.1%
of patients reported that they had a 50% or greater reduction in
seizure frequency over the 12-month period (Brandt 2009). Al-
though all of the studies included in our review were of short du-
ration (treatment periods varied from 12 to 14 weeks for all out-
comes), these observations suggest that there should be no decline
in efficacy over longer time periods. However, this hypothesis re-
mains to be investigated and demonstrated by randomised con-
trolled trials of longer durations.
Another review specifically compared the efficacy of pregabalin
and gabapentin by conducting a meta-analysis and by perform-
ing an indirect comparison method (Delahoy 2010). The review
reported that pregabalin was more efficacious than gabapentin.
Specifically, at the highest doses of both drugs, 600 mg pregabalin
versus 1800 mg gabapentin, Delahoy 2010 reported an odds ratio
of 2.52 (95% CI 1.21 to 5.27) for the outcome 50% or greater
reduction in seizure frequency, in favour of pregabalin.
The findings of the review byDelahoy 2010 are in contrast to those
of the randomised controlled trial conducted by French 2016 that
we included in this review, and which directly compared prega-
balin and gabapentin. French 2016 demonstrated no significant
difference in efficacy between the two drugs for the outcome 50%
or greater reduction in seizure frequency (RR 0.96, 95% CI 0.82
to 1.12). Furthermore, French 2016 reported that participants
randomised to either of the two treatment groups (median dose
450 mg/d pregabalin andmedian dose 1500 mg/d gabapentin) ex-
perienced comparable percentage reductions in seizure frequency
(58.7%and57.4%medianper cent reduction in seizure frequency,
respectively).
Notably, the review by Delahoy 2010 has the advantage of includ-
ing data from multiple sources and, as a result, includes a larger
sample size. This should, in theory, provide a more accurate esti-
mate of the effect of the two drugs. The study by French 2016,
however, has the benefit of being a direct comparison between
the two drugs which provides more convincing evidence than an
indirect comparison. Specifically, the randomised controlled trial
would be expected to have a more even distribution of patient
characteristics at baseline and would have used a more standard-
ised approach to compare the two drugs than the review.More ran-
domised controlled trials directly comparing the two drugs would
be necessary to appropriately compare their effectiveness and to
enable conclusive findings to be reached.
With regard to the adverse event profile of pregabalin, the two
reviews discussed earlier, Hamandi 2006 and Ryvlin 2008, both
reported somnolence, dizziness, ataxia, and fatigue as the most
commonly reported adverse effects, in keeping with the findings
in this review. Ryvlin 2008 also specified that most adverse effects
were mild to moderate in severity. Additionally, Ryvlin 2008 ob-
served a dose-response relationship in the reporting of adverse ef-
fects. Weight gain was also a common adverse effect, with Ryvlin
2008 reporting that 24% of participants experienced weight gain
whilst receiving pregabalin. In actuality, weight gain was the most
reported adverse effect for patients who participated in the obser-
vational study by Brandt 2009, followed by tiredness and cogni-
tive disturbances.
In another meta-analysis specifically focused on investigating the
adverse event profile of pregabalin (Zaccara 2012), it was shown
that vestibulo-cerebellar and central nervous systemadverse events,
including ataxia and somnolence, were more commonly reported
when pregabalin was used in those with focal epilepsy than when
used for its other clinical indications, including anxiety disorders
and pain disorders. It was suggested that these adverse events may
29Pregabalin add-on for drug-resistant focal epilepsy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
not necessarily be attributable to pregabalin, but could instead be
associated with patient’s concomitant AEDs or could actually be
a symptom of focal epilepsy itself.
In contrast, Ryvlin 2008 appeared to consider the adverse effects
reported by people with epilepsy to be a true representation of the
adverse event profile of pregabalin. Ryvlin 2008 suggested that tol-
erability amongst people with epilepsy can instead be improved by
individualising the dose of pregabalin, namely by using a titration
and dose adjustment protocol, to limit adverse effects. Specifically,
Ryvlin 2008 recognised that 24% of participants withdrew from
trials during the first week of treatment in studies that utilised a
fixed dose of pregabalin. This was compared to a withdrawal rate
of only 3% in studies that used an individualised flexible-dose
regimen. In studies of short duration, adverse effects are the most
common reason for treatment withdrawal. Although this trend
was not recognised in our current review, this outcome, that is
treatment withdrawal within a given time period, may be of inter-
est for future review updates as it would be informative for clinical
practice.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In the short term (12 to 14 weeks), 150 mg/d to 600 mg/d of im-
mediate-release pregabalin, given in a twice- or three-times-daily
regimen, can significantly reduce seizure frequency in adults with
treatment-resistant focal epilepsy. A dose of 600 mg/d immedi-
ate-release pregabalin can also significantly increase seizure free-
dom rates amongst people with treatment-resistant focal epilepsy,
but is associated with a significantly higher treatment withdrawal
rate compared to placebo. Pregabalin was significantly associated
with the following adverse effects: ataxia, dizziness, fatigue, som-
nolence, and weight gain. The evidence suggests that there is no
significant difference in efficacy andharms betweenpregabalin and
some of the other currently available antiepileptic drugs, namely
gabapentin, levetiracetam, and lamotrigine. There are currently no
data regarding the longer-term effectiveness of pregabalin versus
placebo or the effects of pregabalin in children.
Implications for research
To improve clinical decisions, further clinical trials are required
in adults and children with drug-refractory focal epilepsy. These
trials should:
1. compare the efficacy and tolerability of pregabalin with
other adjunctive treatments;
2. be of long-term duration (at least 12 months);
3. assess seizure freedom rates, quality of life, and health
economic outcomes;
4. establish cost-effectiveness and compare it with that of
other antiepileptic drugs.
Further data regarding pregnancy outcomes are also needed, which
will require the recruitment of women taking pregabalin to ongo-
ing pregnancy registries.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arroyo 2004
Methods Randomised, double-blind, PBO-controlled, parallel, multicentre (45 in Europe, Aus-
tralia, and South Africa) trial
3 treatment arms: 1 PBO, 2 PGB.
Participants randomised in blocks of 6, each allocated unique IDnumber. All participants
received 2 capsules 3 times a day, but 2 capsule sizes were used (no further information
available)
Duration of baseline period: 8 weeks. 12-week treatment period included 4- to 8-day
titration period
Participants Adults aged 17 to 73 years (mean 37 years), 50.5% male, all with drug-resistant focal
epilepsy. Participants were on 1 to 4 baseline AEDs
344 patients screened, 288 participants randomised: 97 participants to PBO (mean
baseline 28-day seizure frequency: 23.5); 99 participants to 50 mg/d PGB 3 times a day
(mean baseline 28-day seizure frequency: 26.2); and 92 participants to 200 mg/d PGB
3 times a day (mean baseline 28-day seizure frequency: 19.3)
Interventions Group 1: Placebo
Group 2: PGB 50 mg 3 times a day (150 mg/d; 4-day titration phase)
Group 3: PGB 200 mg 3 times a day (600 mg/d; 8-day titration phase)
Outcomes Primary outcome: reduction in seizure frequency compared to baseline (response ratio)
Secondary outcomes: responder rate, seizure freedom, change in seizure frequency, ad-
verse effects
Notes Study used capsules of 2 sizes, containing 25 mg PGB or PBO (size 1# = small capsules)
and 100 mg PGB or PBO (size 4# = large capsules). It is stated that participants received
2 capsules 3 times a day. 1 patient excluded from ITT in PBO arm, as failed to take
study drugs
Study was sponsored by Pfizer Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random computer-generated code used
stratified by centre using block size of 6
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Medication presented in identical capsules.
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Arroyo 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT analysis per-
formed.
Selective reporting (reporting bias) Low risk All outcomes stated in methods section of
paper were reported in the results, however
there was no protocol available to check a
priori outcomes
Other bias Unclear risk As an EEG was not required to confirm
the above, some of the 18 patients in-
cluded who were stated as having “gener-
alised seizures”, rather than secondary gen-
eralised, may have had primary generalised
epilepsy
Baulac 2010
Methods Randomised, double-blind, PBO- and active-drug-controlled, parallel, multicentre (97
in Europe, Canada, and Australia) trial
3 treatment arms: 1 PBO, 1 PGB, and 1 LTG.
Participants randomised to 1 of 3 treatment arms (no further information available)
Duration of baseline period: 6weeks. 17-week treatment periodwith 2 phases in addition
to a titration phase (1 week of titration for PGB and 5 weeks of titration for LTG).
(Phase I: 11 weeks treatment including 1 week titration for PGB and 5 weeks titration
for LTG; Phase II: 6 weeks treatment)
Participants Adults aged 16 to 82 years (mean 39.4 years), 48.5% male, all with treatment-resistant
focal epilepsy confirmed by history and recent EEG. Participants were on 1 to 3 baseline
AEDs
546 patients screened, 434 participants randomised: 141 participants to PBO (mean
baseline 28-day seizure frequency: 16.38); 152 participants to 150 mg to 300 mg PGB
twice daily (mean baseline 28-day seizure frequency: 21.32); and 141 participants to 150
mg to 300 mg LTG twice daily (mean baseline 28-day seizure frequency: 21.80)
Interventions Group 1: Placebo
Group 2: PGB 150 mg to 300 mg twice daily (300 to 600 mg/d; 1-week titration phase)
Group 3: LTG 150 mg to 300 mg twice daily (300 to 600 mg/d; 5-week titration phase)
Outcomes Primary outcome: change in seizure frequency compared to baseline (response ratio)
Secondary outcomes: responder rate, seizure freedom, adverse effects
Notes One participant randomised to the PBO group failed to take > 1 dose of medication
and was therefore excluded from ITT analysis. No information provided on methods of
randomisation, concealment, or blinding
Study was sponsored by Pfizer Inc.
Risk of bias
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Baulac 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details of method of randomisation.
Allocation concealment (selection bias) Unclear risk No details of allocation concealment.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Same number of capsules administered per
study day per group.No further details pro-
vided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT analysis em-
ployed.
Selective reporting (reporting bias) Low risk All outcomes stated in methods section of
paper were reported in the results, however
there was no protocol available to check a
priori outcomes
Other bias Low risk None detected.
Beydoun 2005
Methods Randomised, double-blind, PBO-controlled, parallel, multicentre (43 in USA and
Canada) trial
3 treatment arms: 1 PBO, 2 PGB.
Participants randomised in blocks of 6, each allocated unique IDnumber. All participants
received 3-times-daily regimen of blinded capsules (no further information available)
Duration of baseline period: 8 weeks. 12-week treatment period with 1-week titration
period
Participants Adults aged 17 to 82 years (mean 39.1 years), 50.2% male, all with treatment-resistant
focal epilepsy confirmed by history and recent EEG. Participants were on 1 to 4 baseline
AEDs
378 patients screened, 313 participants randomised: 98 participants to PBO (mean
baseline 28-day seizure frequency: 25.1); 104 participants to 300 mg PGB twice daily
(mean baseline 28-day seizure frequency: 21.5); and 111 participants to 200 mg PGB 3
times a day (mean baseline 28-day seizure frequency: 21.3)
Interventions Group 1: Placebo
Group 2: 300 mg PGB twice daily (600 mg/d; 1-week titration phase)
Group 3: 200 mg PGB 3 times a day (600 mg/d; 1-week titration phase)
Outcomes Primary outcome: reduction in seizure frequency compared to baseline (response ratio)
Secondary outcomes: responder rate, median percentage change in seizure frequency
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Beydoun 2005 (Continued)
Notes 1 participant randomised to the 300 mg twice-daily group failed to take tablets and was
therefore excluded from ITT analysis. Blinding was broken with 1 participant in the
PBO arm when she became pregnant
Study was sponsored by Pfizer Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised in blocks of 6 and
allocated unique ID number
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk All participants received identical capsules.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT analysis em-
ployed.
Selective reporting (reporting bias) Low risk All outcomes stated in methods section of
paper were reported in the results, however
there was no protocol available to check a
priori outcomes
Other bias Low risk None detected.
Elger 2005
Methods Randomised, double-blind, PBO-controlled, parallel, multicentre (53 in Europe and
Canada) trial
3 treatment arms: 1 PBO, 2 PGB. Participants randomised in blocks of 5, each allocated
unique ID number. All regimens mimicked control group using identical capsules (no
further information available)
Duration of baseline period: 6 weeks. 12-week treatment period
Participants Adults aged 18 to 78 years (mean 40.5 years), 49.9% male, all with treatment-resistant
focal epilepsy confirmed by personal and family history as well as recent EEG
Participants were on 1 to 5 baseline AEDs. 400 patients screened, 341 participants
randomised: 73 participants to PBO (median baseline 28-day seizure frequency: 8.7)
; 137 participants to 300 mg PGB twice daily fixed (median baseline 28-day seizure
frequency: 10); and 131 participants to PGB flexible dosing (median baseline 28-day
seizure frequency: 9.33)
Interventions Group 1: Placebo
Group 2: 300 mg PGB twice-daily fixed dose (600 mg/d)
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Elger 2005 (Continued)
Group 3: 75 mg to 300 mg PGB twice-daily flexible titration at physician’s discretion
(150 to 600 mg/d)
Outcomes Primary outcome: reduction in seizure frequency compared to baseline (response ratio)
Secondary outcomes: responder rate, median percentage change in seizure frequency and
reduction of GTCS in those completing the study, adverse effects
Notes In PGB titration and PBO groups, patients were included with seizure frequency of over
120 a day. Documenting seizures at this frequency is difficult and may be unreliable.
Medium length of follow-up not reported
Study was sponsored by Pfizer Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised using a 1:2:2 ratio
and block sizes of 5
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study medication presented in identical
capsules.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT analysis em-
ployed.
Selective reporting (reporting bias) Low risk All outcomes stated in methods section of
paper were reported in the results, however
there was no protocol available to check a
priori outcomes
Other bias Low risk None detected.
French 2003
Methods Randomised, double-blind, PBO-controlled, parallel, multicentre (71 in the USA and
5 in Canada) trial
5 treatment arms: 1 PBO, 4 PGB. Participants randomised in blocks of 5, each allocated
unique ID number. Capsule sizes varied (no further information available)
Duration of baseline period: 8 weeks. There was no titration; 12-week treatment period
Participants Patients 12 years and above (range 12 to 75 years, mean 38.4 years), 48.1% male, all
with treatment-resistant focal epilepsy. Participants were on 1 to 4 baseline AEDs
586 patients screened, 455 participants randomised: 100 participants to PBO (mean
baseline seizure frequency: 22.3); 88 participants to 50 mg PGB (mean baseline seizure
frequency: 27.4); 88 participants to 150 mg PGB (mean baseline 28-day seizure fre-
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French 2003 (Continued)
quency: 23.1); 90 participants to 300 mg PGB (mean baseline 28-day seizure frequency:
19.1); and 89 participants to 600 mg PGB (mean baseline 28-day seizure frequency: 18.
6)
Interventions Group 1: Placebo
Group 2: 50 mg/d PGB (twice daily)
Group 3: 150 mg/d PGB (twice daily)
Group 4: 300 mg/d PGB (twice daily)
Group 5: 600 mg/d PGB (twice daily)
Outcomes Primary outcome: reduction in seizure frequency compared to baseline (response ratio)
Secondary outcomes: responder rate, pairwise comparisons with PBO, adverse effects
Notes Blinding broken for interim analysis (data obtained were only known to committee who
were not involved in further running of study) and for 1 participant who developed
visual field defect. 2 participants were excluded from ITT analysis (1 withdrew consent,
1 had AEDs changed during baseline period). Seizure frequency and responder rate were
calculated from data collected from seizure diaries and mean calculated over a 4-week
period
Study was sponsored by Pfizer Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used a computer-generated randomised
schedule using block sizes of 5
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study medication presented in identical
capsules.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT analysis em-
ployed.
Selective reporting (reporting bias) Low risk All outcomes stated in methods section of
paper were reported in the results, however
there was no protocol available to check a
priori outcomes
Other bias Unclear risk Possibility of the inclusion of individuals
with primary generalised epilepsy
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French 2014
Methods Randomised, double-blind, placebo-controlled, parallel, multicentre (18 countries) trial
assessing the efficacy and tolerability of controlled-release PGB
3 treatment arms: 1 PBO, 2 PGB
Randomised 1:1:1 to PGB 165 mg/d or PGB 330 mg/d or placebo using a computer-
generated randomisation system
Duration of baseline period: 8 weeks. 14-week double-blind treatment period with 2-
week double-blind dose escalation (titration phase); 1-week taper
Participants Adults aged 18 to 75 years, 47.7% male, all with focal epilepsy. Participants were on 1
to 3 baseline AEDs
400 patients screened, 325 participants randomised: 110 participants to placebo (mean
baseline 28-day seizure frequency: 17.8); 101 participants to PGB165mg (mean baseline
28-day seizure frequency: 13.0); 114 participants to PGB 330 mg (mean baseline 28-
day seizure frequency: 17.0)
Interventions Group 1: Placebo
Group 2: PGB 165 mg/d controlled release
Group 3: PGB 330 mg/d controlled release
Outcomes Primary outcomes: reduction in seizure frequency compared to baseline (response ratio)
Secondary outcomes: responder rate, adverse effects
Notes Clinical trials: NCT01262677
Study sponsored by Pfizer Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation sys-
tem.
Allocation concealment (selection bias) Unclear risk Allocate participants to each of the 3 treat-
ment groups in a 1:1:1 manner. No further
details provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details regarding blinding of partici-
pants and personnel provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT efficacy anal-
ysis performed.
Selective reporting (reporting bias) Low risk All outcomes stated in methods section of
paper were reported in the results
There was no protocol available to check a
priori outcomes.
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French 2014 (Continued)
Other bias Low risk None detected.
French 2016
Methods Randomised, double-blind, parallel, multicentre (56 centres in Eastern and Western
Europe, Asia, South and Central America) trial assessing the efficacy and safety of PGB
and GPN
2 treatment arms: PGB and GPN
Randomised 1:1 to PGB 242 or GPN 242 using a computer-generated randomisation
system
Duration of baseline period: 6 weeks. 21-week double-blind phase (9 weeks of double-
blind dose escalation and 12 weeks of double-blind maintenance phase)
Participants Adults aged 18 to 80 years, 53.3% male, all with drug-resistant focal epilepsy (inade-
quately controlled with ≥ 2 to < 5 prior AEDs). All participants were on 1 to 2 baseline
AEDs
561 patients screened, 484 participants randomised: 242 participants to PGB 450 mg
median dose (mean baseline 28-day seizure frequency: 14.1); 242 participants to GPN
1500 mg median dose (mean baseline 28-day seizure frequency: 13.1)
Interventions Group 1: PGB (150, 300, 450, and 600 mg/d during the 9-week dose escalation phase)
Group 2:GPN (300, 600, 1200, 1500, and 1800mg/d during the 9-week dose escalation
phase)
Outcomes Primary outcome: reduction in seizure frequency (50% or more reduction of seizures
and 75% or more reduction of seizures)
Secondary outcomes: seizure freedom for maintenance phase (last 28-day seizure-free
rates), adverse effects
Notes Clinical trials: NCT00537940
Study was sponsored by Pfizer Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation sys-
tem.
Allocation concealment (selection bias) Unclear risk Allocate participants to each of the 2 treat-
ment groups in a 1:1 manner. No further
details provided
Blinding (performance bias and detection
bias)
All outcomes
Low risk Medication presented in identical tablets.
Identical analysis of results
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French 2016 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT efficacy anal-
ysis performed.
Selective reporting (reporting bias) Low risk All outcomes stated in methods section of
paper were reported in the results
There was no protocol available to check a
priori outcomes.
Other bias Low risk None detected.
Lee 2009
Methods Randomised, double-blind, PBO-controlled, parallel, multicentre (9 in Korea) trial
2 treatment arms: 1 PBO, 1 PGB
Participants randomised to 1 of 2 treatment arms (no further information available)
Duration of baseline period: 6 weeks. 12-week treatment period (no further details
provided)
Participants Participants 18 years and above (mean 34.2 years), 48.3% male, all with treatment-
resistant focal epilepsy. Participants were on 1 to 3 baseline AEDs
209 patients screened, 178 participants randomised: 59 participants to PBO (mean
baseline 28-day seizure frequency: 13.2) and 119 participants to 150 mg to 600 mg PGB
(mean baseline 28-day seizure frequency 13.2)
Interventions Group 1: Placebo
Group 2: 75 mg to 300 mg PGB twice daily (150 to 600 mg/d)
Outcomes Primary outcome: change in seizure frequency (response ratio)
Secondary outcomes: responder rate, seizure freedom, anxiety/depression, sleep, quality
of life, adverse effects
Notes All randomised participants included in ITT analysis. No information provided on
methods of randomisation, concealment, or blinding
Study was sponsored by Pfizer Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised using 2:1 ratio.
No further information given
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No information provided.
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Lee 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT analysis em-
ployed.
Selective reporting (reporting bias) Low risk All outcomes stated in methods section of
paper were reported in the results, however
there was no protocol available to check a
priori outcomes
Other bias Low risk None detected.
Zaccara 2014
Methods Randomised, double-blind, flexible-dose, parallel, multicentre (71 centres in Western
and Eastern Europe, South and Central America, Asia) trial
2 treatment arms: PGB and LEV
Randomised 1:1 to either PGB or LEV using a computer-generated randomisation
system
Duration of baseline phase: 6 weeks; 4-week double-blind dose escalation (titration
phase); 12-week double-blind maintenance phase
Participants Adults aged 18 to 65 years (mean 37 years), all with drug-resistant focal epilepsy (inad-
equately controlled with at least 2, but no more than 5 AEDs). Participants were on 1
to 2 baseline AEDs
633 patients were screened, 509 participants were randomised: 254 participants to PGB
(mean baseline 28-day seizure frequency: 16.2) and 255 participants to LEV (mean
baseline 28-day seizure frequency: 13.9)
Interventions Group 1: PGB twice daily (150, 300, 450, and 600 mg/d)
Group 2: LEV twice daily (1000, 2000, and 3000 mg/d)
Outcomes Primary outcome: reduction in seizure frequency (50% or more reduction of seizures)
Secondary outcomes: seizure freedom for maintenance phase, adverse effects
Notes Clinical trials: NCT00537238
Study was sponsored by Pfizer Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation sys-
tem.
Allocation concealment (selection bias) Unclear risk Allocate participants to each of the 2 treat-
ment group in a 1:1 ratio. No further de-
tails provided
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Zaccara 2014 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details are not provided, however it is likely
that blinding of participants and personnel
was maintained due to the methods used
Medication presented in identical tablets.
Identical analysis of results
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. ITT efficacy anal-
ysis performed.
Selective reporting (reporting bias) Low risk All outcomes stated in methods section of
paper were reported in the results
No protocol available to check a priori out-
comes.
Other bias Low risk None detected.
AED: antiepileptic drug; EEG: electroencephalogram; GPN: gabapentin; GTCS: generalised tonic-clonic seizures; ITT: intention-to-
treat; LEV: levetiracetam; LTG: lamotrigine; PBO: placebo; PGB: pregabalin.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Taghdiri 2015 This previously ongoing study, Bali 2012, was published and excluded from the current review as the participant
sample (including participants with a diagnosis of primary generalised epilepsy) did not meet our inclusion criteria
Characteristics of studies awaiting assessment [ordered by study ID]
Russi 2006
Methods Randomised observational controlled study. 4 treatment arms: 1 LEV fast-rate, 2 LEV slow-rate, 3 PGB fast-rate, 4
PGB slow-rate dosage
Participants 128 patients with refractory focal epilepsy (32 in each treatment arm)
Interventions Group 1: starting dose of 1000 mg twice daily LEV fast rate with weekly increments of 500 mg
Group 2: starting dose of 500 mg twice daily LEV slow rate with weekly increments of 250 mg
Group 3: starting dose of 300 mg twice daily PGB fast rate with weekly increments of 150 mg
Group 4: starting dose of 150 mg twice daily PGB slow rate with weekly increments of 75 mg
Outcomes Rate of withdrawals and continuation to maximum dose
Incidence of adverse effects
43Pregabalin add-on for drug-resistant focal epilepsy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Russi 2006 (Continued)
Notes Study reported in abstract form only. Further details of study are unavailable
Tata 2007
Methods Randomised cross-over trial consisting of 2 treatment arms: 1 PGB, 2 LEV. Participants randomised to groups using
1:1 ratio. Study was open-label. Long-term study duration of minimum 6 months
Participants 28 adults aged 19 to 62 years, 54% male. Participants currently taking different AED without maintaining good
seizure control, stabilised to therapeutic association of valproate and lamotrigine
Interventions Group 1: starting dose of 150 mg to target dose of 600 mg PGB
Group 2: starting dose of 1000 mg to target dose of 3000 mg LEV
Outcomes Seizure freedom
Seizure reduction
Withdrawals
Adverse effects
Notes Study reported in abstract only. Further details of study are unavailable
AED: antiepileptic drug; LEV: levetiracetam; PGB: pregabalin
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D A T A A N D A N A L Y S E S
Comparison 1. Pregabalin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 50% or greater reduction in
seizure frequency - ITT
7 2193 Risk Ratio (IV, Random, 95% CI) 2.28 [1.52, 3.42]
2 50% or greater reduction in
seizure frequency - best-case
analysis
7 2193 Risk Ratio (IV, Random, 95% CI) 3.57 [2.17, 5.86]
3 50% or greater reduction in
seizure frequency - worst-case
analysis
7 2193 Risk Ratio (IV, Random, 95% CI) 1.15 [0.92, 1.43]
4 Seizure freedom 4 1125 Risk Ratio (M-H, Fixed, 95% CI) 3.94 [1.50, 10.37]
5 Treatment withdrawal for any
reason
7 2193 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.11, 1.65]
6 Treatment withdrawal due to
adverse effects
7 2193 Risk Ratio (M-H, Fixed, 95% CI) 2.65 [1.88, 3.74]
7 Ataxia 6 1868 Risk Ratio (M-H, Fixed, 99% CI) 3.90 [2.05, 7.42]
8 Dizziness 7 2193 Risk Ratio (M-H, Fixed, 99% CI) 3.15 [2.23, 4.44]
9 Fatigue 7 2193 Risk Ratio (M-H, Fixed, 99% CI) 1.34 [0.93, 1.94]
10 Headache 5 1555 Risk Ratio (M-H, Fixed, 99% CI) 0.63 [0.42, 0.93]
11 Nausea 4 1267 Risk Ratio (M-H, Fixed, 99% CI) 1.20 [0.56, 2.58]
12 Somnolence 7 2193 Risk Ratio (M-H, Fixed, 99% CI) 2.15 [1.50, 3.09]
13 Weight gain 7 2193 Risk Ratio (M-H, Fixed, 99% CI) 5.02 [2.49, 10.10]
Comparison 2. Pregabalin versus placebo - subgroup analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 50% or greater reduction in
seizure frequency - ITT
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 50 mg/d pregabalin 1 188 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.52, 2.12]
1.2 150 mg/d pregabalin 2 384 Risk Ratio (M-H, Fixed, 95% CI) 2.22 [1.36, 3.63]
1.3 300 mg/d pregabalin 1 190 Risk Ratio (M-H, Fixed, 95% CI) 2.86 [1.65, 4.94]
1.4 600 mg/d pregabalin 4 901 Risk Ratio (M-H, Fixed, 95% CI) 4.62 [3.34, 6.39]
1.5 Titrated dose of pregabalin
(150 to 600 mg/d)
3 675 Risk Ratio (M-H, Fixed, 95% CI) 1.76 [1.35, 2.30]
1.6 165 mg/d pregabalin
(controlled release)
1 211 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.72, 1.48]
1.7 330 mg/d pregabalin
(controlled release)
1 224 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.91, 1.75]
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2 50% or greater reduction in
seizure frequency - best-case
analysis
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 50 mg/d pregabalin 1 188 Risk Ratio (M-H, Fixed, 95% CI) 1.87 [1.03, 3.40]
2.2 150 mg/d pregabalin 2 384 Risk Ratio (M-H, Fixed, 95% CI) 3.18 [2.00, 5.06]
2.3 300 mg/d pregabalin 1 190 Risk Ratio (M-H, Fixed, 95% CI) 4.37 [2.61, 7.29]
2.4 600 mg/d pregabalin 4 901 Risk Ratio (M-H, Fixed, 95% CI) 7.72 [5.64, 10.57]
2.5 Titrated dose of pregabalin
(150 to 600 mg/d)
3 675 Risk Ratio (M-H, Fixed, 95% CI) 2.86 [2.24, 3.65]
2.6 165 mg/d pregabalin
(controlled release)
1 211 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.92, 1.79]
2.7 330 mg/d pregabalin
(controlled release)
1 224 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [1.21, 2.20]
3 50% or greater reduction in
seizure frequency - worst-case
analysis
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 50 mg/d pregabalin 1 188 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.30, 0.99]
3.2 150 mg/d pregabalin 2 384 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.38]
3.3 300 mg/d pregabalin 1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.98, 2.23]
3.4 600 mg/d pregabalin 4 901 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [1.42, 2.09]
3.5 Titrated dose of pregabalin
(150 to 600 mg/d)
3 675 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.76, 1.12]
3.6 165 mg/d pregabalin
(controlled release)
1 211 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.57, 1.09]
3.7 330 mg/d pregabalin
(controlled release)
1 224 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.72, 1.28]
4 Seizure freedom 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 600 mg/d 2 523 Risk Ratio (M-H, Fixed, 95% CI) 6.92 [1.31, 36.70]
4.2 Titrated dose of pregabalin
(150 to 600 mg/d)
3 675 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.83, 6.89]
5 Treatment withdrawal for any
reason
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 50 mg/d pregabalin 1 188 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.40, 1.89]
5.2 150 mg/d pregabalin 2 384 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.41, 1.28]
5.3 300 mg/d pregabalin 1 190 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [0.85, 3.10]
5.4 600 mg/d pregabalin 4 901 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [1.42, 2.40]
5.5 Titrated dose of pregabalin
(150 to 600 mg/d)
3 675 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.89, 1.62]
5.6 165 mg/d pregabalin
(controlled release)
1 211 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.36, 1.86]
5.7 330 mg/d pregabalin
(controlled release)
1 224 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.59, 2.46]
6 Treatment withdrawal due to
adverse effects
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 50 mg/d pregabalin 1 188 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.43, 4.31]
6.2 150 mg/d pregabalin 2 384 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.45, 2.32]
6.3 300 mg/d pregabalin 1 190 Risk Ratio (M-H, Fixed, 95% CI) 2.89 [1.07, 7.78]
6.4 600 mg/d pregabalin 4 901 Risk Ratio (M-H, Fixed, 95% CI) 3.78 [2.47, 5.81]
6.5 Titrated dose of pregabalin
(150 to 600 mg/d)
3 675 Risk Ratio (M-H, Fixed, 95% CI) 2.26 [1.30, 3.95]
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6.6 165 mg/d pregabalin
(controlled release)
1 211 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.22, 5.27]
6.7 330 mg/d pregabalin
(controlled release)
1 224 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [0.70, 9.45]
7 Ataxia 6 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
7.1 50 mg/d pregabalin 1 188 Risk Ratio (M-H, Fixed, 99% CI) 1.14 [0.14, 9.00]
7.2 150 mg/d pregabalin 2 384 Risk Ratio (M-H, Fixed, 99% CI) 1.98 [0.56, 7.01]
7.3 300 mg/d pregabalin 1 190 Risk Ratio (M-H, Fixed, 99% CI) 3.33 [0.62, 17.81]
7.4 600 mg/d pregabalin 4 901 Risk Ratio (M-H, Fixed, 99% CI) 4.49 [2.25, 8.95]
7.5 Titrated dose pregabalin
(150 to 600 mg/d)
3 675 Risk Ratio (M-H, Fixed, 99% CI) 4.46 [1.28, 15.48]
8 Dizziness 7 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
8.1 50 mg/d pregabalin 1 188 Risk Ratio (M-H, Fixed, 99% CI) 1.01 [0.31, 3.33]
8.2 150 mg/d pregabalin 2 384 Risk Ratio (M-H, Fixed, 99% CI) 2.04 [0.99, 4.22]
8.3 300 mg/d pregabalin 1 190 Risk Ratio (M-H, Fixed, 99% CI) 3.46 [1.39, 8.62]
8.4 600 mg/d pregabalin 4 901 Risk Ratio (M-H, Fixed, 99% CI) 3.72 [2.42, 5.69]
8.5 Titrated dose of pregabalin
(150 to 600 mg/d pregabalin)
3 675 Risk Ratio (M-H, Fixed, 99% CI) 3.08 [1.80, 5.28]
8.6 165 mg/d pregabalin
(controlled release)
1 211 Risk Ratio (M-H, Fixed, 99% CI) 5.99 [0.85, 42.02]
8.7 330 mg/d pregabalin
(controlled release)
1 224 Risk Ratio (M-H, Fixed, 99% CI) 5.31 [0.76, 37.30]
9 Fatigue 7 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
9.1 50 mg/d pregabalin 1 188 Risk Ratio (M-H, Fixed, 99% CI) 0.71 [0.17, 2.94]
9.2 150 mg/d pregabalin 2 384 Risk Ratio (M-H, Fixed, 99% CI) 1.09 [0.50, 2.39]
9.3 300 mg/d pregabalin 1 190 Risk Ratio (M-H, Fixed, 99% CI) 1.53 [0.49, 4.76]
9.4 600 mg/d pregabalin 4 901 Risk Ratio (M-H, Fixed, 99% CI) 1.50 [0.89, 2.52]
9.5 Titrated dose of pregabalin
(150 to 600 mg/d)
3 675 Risk Ratio (M-H, Fixed, 99% CI) 1.15 [0.69, 1.91]
9.6 165 mg/d pregabalin
(controlled release)
1 211 Risk Ratio (M-H, Fixed, 99% CI) 3.27 [0.17, 62.62]
9.7 330 mg/d pregabalin
(controlled release)
1 224 Risk Ratio (M-H, Fixed, 99% CI) 5.79 [0.37, 91.55]
10 Headache 5 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
10.1 50 mg/d pregabalin 1 188 Risk Ratio (M-H, Fixed, 99% CI) 0.52 [0.16, 1.77]
10.2 150 mg/d pregabalin 2 384 Risk Ratio (M-H, Fixed, 99% CI) 0.53 [0.24, 1.17]
10.3 300 mg/d pregabalin 1 190 Risk Ratio (M-H, Fixed, 99% CI) 0.43 [0.12, 1.57]
10.4 600 mg/d pregabalin 3 588 Risk Ratio (M-H, Fixed, 99% CI) 0.63 [0.33, 1.19]
10.5 Titrated dose of
pregabalin (150 to 600 mg/d)
3 675 Risk Ratio (M-H, Fixed, 99% CI) 0.74 [0.44, 1.25]
11 Nausea 4 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
11.1 150 mg/d pregabalin 1 196 Risk Ratio (M-H, Fixed, 99% CI) 1.31 [0.34, 5.00]
11.2 600 mg/d pregabalin 3 712 Risk Ratio (M-H, Fixed, 99% CI) 1.18 [0.51, 2.75]
11.3 Titrated dose of
pregabalin (150 to 600 mg/d)
1 204 Risk Ratio (M-H, Fixed, 99% CI) 1.11 [0.12, 10.05]
11.4 165 mg/d pregabalin
(controlled release)
1 211 Risk Ratio (M-H, Fixed, 99% CI) 3.27 [0.17, 62.62]
11.5 330 mg/d pregabalin
(controlled release)
1 224 Risk Ratio (M-H, Fixed, 99% CI) 0.96 [0.03, 36.26]
12 Somnolence 7 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
12.1 50 mg/d pregabalin 1 188 Risk Ratio (M-H, Fixed, 99% CI) 0.93 [0.31, 2.78]
12.2 150 mg/d pregabalin 2 384 Risk Ratio (M-H, Fixed, 99% CI) 1.26 [0.58, 2.74]
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12.3 300 mg/d pregabalin 1 190 Risk Ratio (M-H, Fixed, 99% CI) 1.62 [0.63, 4.12]
12.4 600 mg/d pregabalin 4 901 Risk Ratio (M-H, Fixed, 99% CI) 2.57 [1.64, 4.03]
12.5 Titrated dose of
pregabalin
3 675 Risk Ratio (M-H, Fixed, 99% CI) 2.35 [1.31, 4.19]
12.6 165 mg/d pregabalin
(controlled release)
1 211 Risk Ratio (M-H, Fixed, 99% CI) 2.18 [0.24, 19.70]
12.7 330 mg/d pregabalin
(controlled release)
1 224 Risk Ratio (M-H, Fixed, 99% CI) 2.89 [0.36, 23.05]
13 Weight gain 7 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
13.1 50 mg/d pregabalin 1 188 Risk Ratio (M-H, Fixed, 99% CI) 3.40 [0.05, 224.69]
13.2 150 mg/d pregabalin 2 384 Risk Ratio (M-H, Fixed, 99% CI) 3.85 [0.64, 23.35]
13.3 300 mg/d pregabalin 1 190 Risk Ratio (M-H, Fixed, 99% CI) 14.43 [0.34, 620.87]
13.4 600 mg/d pregabalin 4 901 Risk Ratio (M-H, Fixed, 99% CI) 5.88 [2.52, 13.73]
13.5 Titrated dose of
pregabalin (150 to 600 mg/d
pregabalin)
3 675 Risk Ratio (M-H, Fixed, 99% CI) 3.64 [1.49, 8.87]
13.6 165 mg/d pregabalin
(controlled release)
1 211 Risk Ratio (M-H, Fixed, 99% CI) 3.26 [0.05, 215.86]
13.7 330 mg/d pregabalin
(controlled release)
1 224 Risk Ratio (M-H, Fixed, 99% CI) 14.48 [0.34, 613.54]
Comparison 3. Pregabalin versus active comparator
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 50% or greater reduction in
seizure frequency
3 1286 Risk Ratio (IV, Random, 95% CI) 1.03 [0.85, 1.25]
2 50% or greater reduction in
seizure frequency - best-case
analysis
3 1286 Risk Ratio (IV, Random, 95% CI) 1.60 [1.17, 2.19]
3 50% or greater reduction in
seizure frequency - worst-case
analysis
3 1286 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.62, 0.74]
4 Seizure freedom 2 802 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.37, 0.95]
5 Treatment withdrawal for any
reason
3 1286 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.76, 1.13]
6 Treatment withdrawal due to
adverse effects
3 1286 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.73, 1.48]
7 Ataxia 1 293 Risk Ratio (M-H, Fixed, 99% CI) 1.72 [0.54, 5.55]
8 Dizziness 3 1286 Risk Ratio (IV, Random, 99% CI) 1.64 [0.85, 3.16]
9 Fatigue 1 293 Risk Ratio (M-H, Fixed, 99% CI) 1.72 [0.77, 3.83]
10 Headache 3 1286 Risk Ratio (IV, Random, 99% CI) 0.83 [0.41, 1.65]
11 Nausea 1 509 Risk Ratio (M-H, Fixed, 99% CI) 0.20 [0.04, 1.01]
12 Somnolence 3 1286 Risk Ratio (M-H, Fixed, 99% CI) 1.16 [0.88, 1.53]
13 Weight gain 3 1286 Risk Ratio (IV, Random, 99% CI) 2.87 [0.94, 8.75]
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Comparison 4. Pregabalin versus active comparator - subgroup analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 50% or greater reduction in
seizure frequency
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Pregabalin versus
lamotrigine
1 293 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [1.03, 2.12]
1.2 Pregabalin versus
levetiracetam
1 509 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.80, 1.11]
1.3 Pregabalin versus
gabapentin
1 484 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.82, 1.12]
2 50% or greater reduction in
seizure frequency - best-case
analysis
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Pregabalin versus
lamotrigine
1 293 Risk Ratio (M-H, Fixed, 95% CI) 2.73 [1.99, 3.74]
2.2 Pregabalin versus
levetiracetam
1 509 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [1.11, 1.46]
2.3 Pregabalin versus
gabapentin
1 484 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [1.18, 1.52]
3 50% or greater reduction in
seizure frequency - worst-case
analysis
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Pregabalin versus
lamotrigine
1 293 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.52, 0.88]
3.2 Pregabalin versus
levetiracetam
1 509 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.62, 0.82]
3.3 Pregabalin versus
gabapentin
1 484 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.57, 0.73]
4 Seizure freedom 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Pregabalin versus
lamotrigine
1 293 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.40, 4.83]
4.2 Pregabalin versus
levetiracetam
1 509 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.30, 0.85]
5 Treatment withdrawal for any
reason
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Pregabalin versus
lamotrigine
1 293 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.75, 1.52]
5.2 Pregabalin versus
levetiracetam
1 509 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.71, 1.49]
5.3 Pregabalin versus
gabapentin
1 484 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.57, 1.07]
6 Treatment withdrawal due to
adverse effects
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Pregabalin versus
lamotrigine
1 293 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.53, 1.48]
6.2 Pregabalin versus
levetiracetam
1 509 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.66, 2.54]
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6.3 Pregabalin versus
gabapentin
1 484 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.54, 2.11]
7 Dizziness 3 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
7.1 Pregabalin versus
lamotrigine
1 293 Risk Ratio (M-H, Fixed, 99% CI) 2.94 [1.32, 6.52]
7.2 Pregabalin versus
levetiracetam
1 509 Risk Ratio (M-H, Fixed, 99% CI) 1.44 [0.89, 2.34]
7.3 Pregabalin versus
gabapentin
1 484 Risk Ratio (M-H, Fixed, 99% CI) 1.1 [0.51, 2.35]
8 Headache 3 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
8.1 Pregabalin versus
lamotrigine
1 293 Risk Ratio (M-H, Fixed, 99% CI) 0.52 [0.26, 1.05]
8.2 Pregabalin versus
levetiracetam
1 509 Risk Ratio (M-H, Fixed, 99% CI) 1.25 [0.64, 2.45]
8.3 Pregabalin versus
gabapentin
1 484 Risk Ratio (M-H, Fixed, 99% CI) 0.85 [0.38, 1.92]
9 Nausea 1 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
9.1 Pregabalin versus
levetiracetam
1 509 Risk Ratio (M-H, Fixed, 99% CI) 0.20 [0.04, 1.01]
10 Somnolence 3 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
10.1 Pregabalin versus
lamotrigine
1 293 Risk Ratio (M-H, Fixed, 99% CI) 1.99 [0.91, 4.33]
10.2 Pregabalin versus
levetiracetam
1 509 Risk Ratio (M-H, Fixed, 99% CI) 1.09 [0.77, 1.54]
10.3 Pregabalin versus
gabapentin
1 484 Risk Ratio (M-H, Fixed, 99% CI) 1.0 [0.56, 1.78]
11 Weight gain 3 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
11.1 Pregabalin versus
lamotrigine
1 293 Risk Ratio (M-H, Fixed, 99% CI) 4.33 [0.86, 21.68]
11.2 Pregabalin versus
levetiracetam
1 509 Risk Ratio (M-H, Fixed, 99% CI) 4.82 [1.39, 16.74]
11.3 Pregabalin versus
gabapentin
1 484 Risk Ratio (M-H, Fixed, 99% CI) 1.46 [0.60, 3.58]
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Analysis 1.1. Comparison 1 Pregabalin versus placebo, Outcome 1 50% or greater reduction in seizure
frequency - ITT.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 1 50% or greater reduction in seizure frequency - ITT
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Arroyo 2004 54/191 6/97 10.9 % 4.57 [ 2.04, 10.25 ]
Baulac 2010 54/152 30/141 16.2 % 1.67 [ 1.14, 2.45 ]
Beydoun 2005 98/215 9/98 12.9 % 4.96 [ 2.62, 9.41 ]
Elger 2005 103/268 8/73 12.5 % 3.51 [ 1.79, 6.86 ]
French 2003 121/355 14/100 14.6 % 2.43 [ 1.47, 4.04 ]
French 2014 88/215 39/110 17.2 % 1.15 [ 0.86, 1.56 ]
Lee 2009 55/119 19/59 15.8 % 1.44 [ 0.94, 2.18 ]
Total (95% CI) 1515 678 100.0 % 2.28 [ 1.52, 3.42 ]
Total events: 573 (Pregabalin), 125 (Placebo)
Heterogeneity: Tau2 = 0.23; Chi2 = 29.69, df = 6 (P = 0.00004); I2 =80%
Test for overall effect: Z = 3.96 (P = 0.000076)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Pregabalin versus placebo, Outcome 2 50% or greater reduction in seizure
frequency - best-case analysis.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 2 50% or greater reduction in seizure frequency - best-case analysis
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Arroyo 2004 88/191 6/97 11.9 % 7.45 [ 3.38, 16.41 ]
Baulac 2010 100/152 30/141 15.8 % 3.09 [ 2.21, 4.33 ]
Beydoun 2005 157/215 9/98 13.4 % 7.95 [ 4.24, 14.90 ]
Elger 2005 191/268 8/73 13.1 % 6.50 [ 3.37, 12.56 ]
French 2003 185/355 14/100 14.5 % 3.72 [ 2.27, 6.11 ]
French 2014 112/215 39/110 16.1 % 1.47 [ 1.11, 1.95 ]
Lee 2009 65/119 19/59 15.3 % 1.70 [ 1.13, 2.54 ]
Total (95% CI) 1515 678 100.0 % 3.57 [ 2.17, 5.86 ]
Total events: 898 (Pregabalin), 125 (Placebo)
Heterogeneity: Tau2 = 0.38; Chi2 = 49.38, df = 6 (P<0.00001); I2 =88%
Test for overall effect: Z = 5.02 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Pregabalin versus placebo, Outcome 3 50% or greater reduction in seizure
frequency - worst-case analysis.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 3 50% or greater reduction in seizure frequency - worst-case analysis
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Arroyo 2004 54/191 19/97 11.2 % 1.44 [ 0.91, 2.29 ]
Baulac 2010 54/152 65/141 16.4 % 0.77 [ 0.58, 1.02 ]
Beydoun 2005 98/215 26/98 13.9 % 1.72 [ 1.20, 2.46 ]
Elger 2005 103/268 25/73 14.2 % 1.12 [ 0.79, 1.60 ]
French 2003 121/355 27/100 14.2 % 1.26 [ 0.89, 1.80 ]
French 2014 88/215 51/110 17.1 % 0.88 [ 0.68, 1.14 ]
Lee 2009 55/119 21/59 13.0 % 1.30 [ 0.88, 1.93 ]
Total (95% CI) 1515 678 100.0 % 1.15 [ 0.92, 1.43 ]
Total events: 573 (Pregabalin), 234 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 17.51, df = 6 (P = 0.01); I2 =66%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Pregabalin versus placebo, Outcome 4 Seizure freedom.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 4 Seizure freedom
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Beydoun 2005 17/215 0/98 11.5 % 16.04 [ 0.97, 264.07 ]
Baulac 2010 6/152 1/141 17.4 % 5.57 [ 0.68, 45.66 ]
Elger 2005 8/268 1/73 26.3 % 2.18 [ 0.28, 17.14 ]
Lee 2009 5/119 2/59 44.8 % 1.24 [ 0.25, 6.20 ]
Total (95% CI) 754 371 100.0 % 3.94 [ 1.50, 10.37 ]
Total events: 36 (Pregabalin), 4 (Placebo)
Heterogeneity: Chi2 = 3.37, df = 3 (P = 0.34); I2 =11%
Test for overall effect: Z = 2.78 (P = 0.0055)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Pregabalin versus placebo, Outcome 5 Treatment withdrawal for any reason.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 5 Treatment withdrawal for any reason
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arroyo 2004 34/191 13/97 12.1 % 1.33 [ 0.74, 2.40 ]
Baulac 2010 46/152 35/141 25.5 % 1.22 [ 0.84, 1.77 ]
Beydoun 2005 59/215 17/98 16.4 % 1.58 [ 0.98, 2.57 ]
Elger 2005 88/268 17/73 18.8 % 1.41 [ 0.90, 2.21 ]
French 2003 64/355 13/100 14.2 % 1.39 [ 0.80, 2.41 ]
French 2014 24/215 12/110 11.1 % 1.02 [ 0.53, 1.97 ]
Lee 2009 10/119 2/59 1.9 % 2.48 [ 0.56, 10.95 ]
Total (95% CI) 1515 678 100.0 % 1.35 [ 1.11, 1.65 ]
Total events: 325 (Pregabalin), 109 (Placebo)
Heterogeneity: Chi2 = 2.08, df = 6 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.97 (P = 0.0030)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pregabalin Favours placebo
55Pregabalin add-on for drug-resistant focal epilepsy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 Pregabalin versus placebo, Outcome 6 Treatment withdrawal due to adverse
effects.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 6 Treatment withdrawal due to adverse effects
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arroyo 2004 27/191 6/97 16.5 % 2.29 [ 0.98, 5.35 ]
Baulac 2010 24/152 10/141 21.5 % 2.23 [ 1.10, 4.49 ]
Beydoun 2005 48/215 7/98 19.9 % 3.13 [ 1.47, 6.66 ]
Elger 2005 61/268 5/73 16.3 % 3.32 [ 1.39, 7.97 ]
French 2003 41/355 5/100 16.2 % 2.31 [ 0.94, 5.69 ]
French 2014 11/215 3/110 8.2 % 1.88 [ 0.53, 6.59 ]
Lee 2009 7/119 0/59 1.4 % 7.50 [ 0.44, 129.13 ]
Total (95% CI) 1515 678 100.0 % 2.65 [ 1.88, 3.74 ]
Total events: 219 (Pregabalin), 36 (Placebo)
Heterogeneity: Chi2 = 1.69, df = 6 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 5.55 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pregabalin Favours placebo
56Pregabalin add-on for drug-resistant focal epilepsy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 Pregabalin versus placebo, Outcome 7 Ataxia.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 7 Ataxia
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Arroyo 2004 18/191 3/97 17.1 % 3.05 [ 0.63, 14.70 ]
Baulac 2010 13/152 1/141 4.4 % 12.06 [ 0.85, 171.72 ]
Beydoun 2005 48/215 6/98 35.3 % 3.65 [ 1.25, 10.63 ]
Elger 2005 41/268 3/73 20.2 % 3.72 [ 0.83, 16.73 ]
French 2003 34/355 3/100 20.1 % 3.19 [ 0.70, 14.65 ]
Lee 2009 5/119 0/59 2.9 % 5.50 [ 0.13, 241.69 ]
Total (99% CI) 1300 568 100.0 % 3.90 [ 2.05, 7.42 ]
Total events: 159 (Pregabalin), 16 (Placebo)
Heterogeneity: Chi2 = 1.56, df = 5 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 5.44 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Pregabalin versus placebo, Outcome 8 Dizziness.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 8 Dizziness
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Arroyo 2004 43/191 8/97 13.7 % 2.73 [ 1.07, 6.98 ]
Baulac 2010 38/152 13/141 17.4 % 2.71 [ 1.25, 5.86 ]
Beydoun 2005 88/215 14/98 24.8 % 2.87 [ 1.46, 5.61 ]
Elger 2005 91/268 6/73 12.2 % 4.13 [ 1.47, 11.58 ]
French 2003 88/355 9/100 18.1 % 2.75 [ 1.17, 6.46 ]
French 2014 22/215 2/110 3.4 % 5.63 [ 0.86, 36.82 ]
Lee 2009 46/119 6/59 10.4 % 3.80 [ 1.34, 10.76 ]
Total (99% CI) 1515 678 100.0 % 3.15 [ 2.23, 4.44 ]
Total events: 416 (Pregabalin), 58 (Placebo)
Heterogeneity: Chi2 = 2.01, df = 6 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 8.59 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Pregabalin versus placebo, Outcome 9 Fatigue.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 9 Fatigue
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Arroyo 2004 26/191 11/97 18.3 % 1.20 [ 0.50, 2.86 ]
Baulac 2010 26/152 24/141 31.2 % 1.00 [ 0.52, 1.95 ]
Beydoun 2005 27/215 5/98 8.6 % 2.46 [ 0.73, 8.29 ]
Elger 2005 47/268 10/73 19.7 % 1.28 [ 0.56, 2.94 ]
French 2003 32/355 8/100 15.6 % 1.13 [ 0.42, 2.99 ]
French 2014 9/215 1/110 1.7 % 4.60 [ 0.31, 68.40 ]
Lee 2009 11/119 3/59 5.0 % 1.82 [ 0.36, 9.25 ]
Total (99% CI) 1515 678 100.0 % 1.34 [ 0.93, 1.94 ]
Total events: 178 (Pregabalin), 62 (Placebo)
Heterogeneity: Chi2 = 4.87, df = 6 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Pregabalin versus placebo, Outcome 10 Headache.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 10 Headache
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Arroyo 2004 17/191 15/97 21.8 % 0.58 [ 0.25, 1.35 ]
Baulac 2010 18/152 28/141 31.9 % 0.60 [ 0.29, 1.22 ]
Elger 2005 28/268 8/73 13.8 % 0.95 [ 0.36, 2.53 ]
French 2003 24/355 13/100 22.3 % 0.52 [ 0.23, 1.20 ]
Lee 2009 9/119 7/59 10.3 % 0.64 [ 0.19, 2.18 ]
Total (99% CI) 1085 470 100.0 % 0.63 [ 0.42, 0.93 ]
Total events: 96 (Pregabalin), 71 (Placebo)
Heterogeneity: Chi2 = 1.66, df = 4 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Pregabalin versus placebo, Outcome 11 Nausea.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 11 Nausea
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Arroyo 2004 13/191 6/97 38.5 % 1.10 [ 0.32, 3.76 ]
Beydoun 2005 11/215 6/98 39.9 % 0.84 [ 0.23, 2.97 ]
Elger 2005 15/268 2/73 15.2 % 2.04 [ 0.30, 13.78 ]
French 2014 4/215 1/110 6.4 % 2.05 [ 0.12, 35.88 ]
Total (99% CI) 889 378 100.0 % 1.20 [ 0.56, 2.58 ]
Total events: 43 (Pregabalin), 15 (Placebo)
Heterogeneity: Chi2 = 1.32, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Pregabalin versus placebo, Outcome 12 Somnolence.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 12 Somnolence
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Arroyo 2004 33/191 7/97 12.4 % 2.39 [ 0.86, 6.66 ]
Baulac 2010 30/152 15/141 20.9 % 1.86 [ 0.87, 3.95 ]
Beydoun 2005 57/215 12/98 22.1 % 2.17 [ 1.02, 4.61 ]
Elger 2005 49/268 6/73 12.6 % 2.22 [ 0.77, 6.43 ]
French 2003 65/355 11/100 23.0 % 1.66 [ 0.76, 3.66 ]
French 2014 10/215 2/110 3.5 % 2.56 [ 0.36, 18.38 ]
Lee 2009 26/119 3/59 5.4 % 4.30 [ 0.94, 19.57 ]
Total (99% CI) 1515 678 100.0 % 2.15 [ 1.50, 3.09 ]
Total events: 270 (Pregabalin), 56 (Placebo)
Heterogeneity: Chi2 = 2.47, df = 6 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 5.45 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Pregabalin versus placebo, Outcome 13 Weight gain.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 1 Pregabalin versus placebo
Outcome: 13 Weight gain
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Arroyo 2004 20/191 2/97 13.6 % 5.08 [ 0.77, 33.39 ]
Baulac 2010 14/152 2/141 10.7 % 6.49 [ 0.95, 44.46 ]
Beydoun 2005 38/215 2/98 14.1 % 8.66 [ 1.37, 54.65 ]
Elger 2005 53/268 5/73 40.4 % 2.89 [ 0.91, 9.17 ]
French 2003 20/355 0/100 4.0 % 11.63 [ 0.29, 459.09 ]
French 2014 8/215 0/110 3.4 % 8.74 [ 0.21, 366.41 ]
Lee 2009 14/119 2/59 13.8 % 3.47 [ 0.52, 23.28 ]
Total (99% CI) 1515 678 100.0 % 5.02 [ 2.49, 10.10 ]
Total events: 167 (Pregabalin), 13 (Placebo)
Heterogeneity: Chi2 = 2.96, df = 6 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 5.94 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 1 50% or greater
reduction in seizure frequency - ITT.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 1 50% or greater reduction in seizure frequency - ITT
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 50 mg/d pregabalin
French 2003 13/88 14/100 100.0 % 1.06 [ 0.52, 2.12 ]
Subtotal (95% CI) 88 100 100.0 % 1.06 [ 0.52, 2.12 ]
Total events: 13 (Pregabalin), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 150 mg/d pregabalin
Arroyo 2004 14/99 6/97 31.6 % 2.29 [ 0.92, 5.71 ]
French 2003 27/88 14/100 68.4 % 2.19 [ 1.23, 3.91 ]
Subtotal (95% CI) 187 197 100.0 % 2.22 [ 1.36, 3.63 ]
Total events: 41 (Pregabalin), 20 (Placebo)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 3.19 (P = 0.0014)
3 300 mg/d pregabalin
French 2003 36/90 14/100 100.0 % 2.86 [ 1.65, 4.94 ]
Subtotal (95% CI) 90 100 100.0 % 2.86 [ 1.65, 4.94 ]
Total events: 36 (Pregabalin), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.76 (P = 0.00017)
4 600 mg/d pregabalin
Arroyo 2004 40/92 6/97 14.0 % 7.03 [ 3.13, 15.79 ]
Beydoun 2005 98/215 9/98 29.6 % 4.96 [ 2.62, 9.41 ]
Elger 2005 62/137 8/73 25.0 % 4.13 [ 2.09, 8.15 ]
French 2003 45/89 14/100 31.5 % 3.61 [ 2.13, 6.12 ]
Subtotal (95% CI) 533 368 100.0 % 4.62 [ 3.34, 6.39 ]
Total events: 245 (Pregabalin), 37 (Placebo)
Heterogeneity: Chi2 = 2.02, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 9.25 (P < 0.00001)
5 Titrated dose of pregabalin (150 to 600 mg/d)
Baulac 2010 54/152 30/141 46.6 % 1.67 [ 1.14, 2.45 ]
Elger 2005 41/131 8/73 15.4 % 2.86 [ 1.42, 5.76 ]
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(. . . Continued)
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lee 2009 55/119 19/59 38.0 % 1.44 [ 0.94, 2.18 ]
Subtotal (95% CI) 402 273 100.0 % 1.76 [ 1.35, 2.30 ]
Total events: 150 (Pregabalin), 57 (Placebo)
Heterogeneity: Chi2 = 2.83, df = 2 (P = 0.24); I2 =29%
Test for overall effect: Z = 4.21 (P = 0.000025)
6 165 mg/d pregabalin (controlled release)
French 2014 37/101 39/110 100.0 % 1.03 [ 0.72, 1.48 ]
Subtotal (95% CI) 101 110 100.0 % 1.03 [ 0.72, 1.48 ]
Total events: 37 (Pregabalin), 39 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
7 330 mg/d pregabalin (controlled release)
French 2014 51/114 39/110 100.0 % 1.26 [ 0.91, 1.75 ]
Subtotal (95% CI) 114 110 100.0 % 1.26 [ 0.91, 1.75 ]
Total events: 51 (Pregabalin), 39 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 2.2. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 2 50% or greater
reduction in seizure frequency - best-case analysis.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 2 50% or greater reduction in seizure frequency - best-case analysis
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 50 mg/d pregabalin
French 2003 23/88 14/100 100.0 % 1.87 [ 1.03, 3.40 ]
Subtotal (95% CI) 88 100 100.0 % 1.87 [ 1.03, 3.40 ]
Total events: 23 (Pregabalin), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
2 150 mg/d pregabalin
Arroyo 2004 25/99 6/97 31.6 % 4.08 [ 1.75, 9.51 ]
French 2003 34/88 14/100 68.4 % 2.76 [ 1.59, 4.80 ]
Subtotal (95% CI) 187 197 100.0 % 3.18 [ 2.00, 5.06 ]
Total events: 59 (Pregabalin), 20 (Placebo)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 4.88 (P < 0.00001)
3 300 mg/d pregabalin
French 2003 55/90 14/100 100.0 % 4.37 [ 2.61, 7.29 ]
Subtotal (95% CI) 90 100 100.0 % 4.37 [ 2.61, 7.29 ]
Total events: 55 (Pregabalin), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.63 (P < 0.00001)
4 600 mg/d pregabalin
Arroyo 2004 63/92 6/97 14.0 % 11.07 [ 5.04, 24.33 ]
Beydoun 2005 157/215 9/98 29.6 % 7.95 [ 4.24, 14.90 ]
Elger 2005 119/137 8/73 25.0 % 7.93 [ 4.11, 15.29 ]
French 2003 73/89 14/100 31.5 % 5.86 [ 3.57, 9.62 ]
Subtotal (95% CI) 533 368 100.0 % 7.72 [ 5.64, 10.57 ]
Total events: 412 (Pregabalin), 37 (Placebo)
Heterogeneity: Chi2 = 2.01, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 12.74 (P < 0.00001)
5 Titrated dose of pregabalin (150 to 600 mg/d)
Baulac 2010 100/152 30/141 46.6 % 3.09 [ 2.21, 4.33 ]
Elger 2005 72/131 8/73 15.4 % 5.02 [ 2.56, 9.82 ]
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(. . . Continued)
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lee 2009 65/119 19/59 38.0 % 1.70 [ 1.13, 2.54 ]
Subtotal (95% CI) 402 273 100.0 % 2.86 [ 2.24, 3.65 ]
Total events: 237 (Pregabalin), 57 (Placebo)
Heterogeneity: Chi2 = 9.28, df = 2 (P = 0.01); I2 =78%
Test for overall effect: Z = 8.43 (P < 0.00001)
6 165 mg/d pregabalin (controlled release)
French 2014 46/101 39/110 100.0 % 1.28 [ 0.92, 1.79 ]
Subtotal (95% CI) 101 110 100.0 % 1.28 [ 0.92, 1.79 ]
Total events: 46 (Pregabalin), 39 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
7 330 mg/d pregabalin (controlled release)
French 2014 66/114 39/110 100.0 % 1.63 [ 1.21, 2.20 ]
Subtotal (95% CI) 114 110 100.0 % 1.63 [ 1.21, 2.20 ]
Total events: 66 (Pregabalin), 39 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.24 (P = 0.0012)
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Analysis 2.3. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 3 50% or greater
reduction in seizure frequency - worst-case analysis.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 3 50% or greater reduction in seizure frequency - worst-case analysis
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 50 mg/d pregabalin
French 2003 13/88 27/100 100.0 % 0.55 [ 0.30, 0.99 ]
Subtotal (95% CI) 88 100 100.0 % 0.55 [ 0.30, 0.99 ]
Total events: 13 (Pregabalin), 27 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
2 150 mg/d pregabalin
Arroyo 2004 14/99 19/97 43.2 % 0.72 [ 0.38, 1.36 ]
French 2003 27/88 27/100 56.8 % 1.14 [ 0.72, 1.78 ]
Subtotal (95% CI) 187 197 100.0 % 0.96 [ 0.66, 1.38 ]
Total events: 41 (Pregabalin), 46 (Placebo)
Heterogeneity: Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 0.23 (P = 0.82)
3 300 mg/d pregabalin
French 2003 36/90 27/100 100.0 % 1.48 [ 0.98, 2.23 ]
Subtotal (95% CI) 90 100 100.0 % 1.48 [ 0.98, 2.23 ]
Total events: 36 (Pregabalin), 27 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.060)
4 600 mg/d pregabalin
Arroyo 2004 40/92 19/97 16.5 % 2.22 [ 1.39, 3.54 ]
Beydoun 2005 98/215 26/98 31.8 % 1.72 [ 1.20, 2.46 ]
Elger 2005 62/137 25/73 29.1 % 1.32 [ 0.92, 1.91 ]
French 2003 45/89 27/100 22.7 % 1.87 [ 1.28, 2.74 ]
Subtotal (95% CI) 533 368 100.0 % 1.72 [ 1.42, 2.09 ]
Total events: 245 (Pregabalin), 97 (Placebo)
Heterogeneity: Chi2 = 3.32, df = 3 (P = 0.34); I2 =10%
Test for overall effect: Z = 5.48 (P < 0.00001)
5 Titrated dose of pregabalin (150 to 600 mg/d)
Baulac 2010 54/152 65/141 52.8 % 0.77 [ 0.58, 1.02 ]
Elger 2005 41/131 25/73 25.2 % 0.91 [ 0.61, 1.37 ]
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(. . . Continued)
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lee 2009 55/119 21/59 22.0 % 1.30 [ 0.88, 1.93 ]
Subtotal (95% CI) 402 273 100.0 % 0.92 [ 0.76, 1.12 ]
Total events: 150 (Pregabalin), 111 (Placebo)
Heterogeneity: Chi2 = 4.49, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 0.80 (P = 0.43)
6 165 mg/d pregabalin (controlled release)
French 2014 37/101 51/110 100.0 % 0.79 [ 0.57, 1.09 ]
Subtotal (95% CI) 101 110 100.0 % 0.79 [ 0.57, 1.09 ]
Total events: 37 (Pregabalin), 51 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
7 330 mg/d pregabalin (controlled release)
French 2014 51/114 51/110 100.0 % 0.96 [ 0.72, 1.28 ]
Subtotal (95% CI) 114 110 100.0 % 0.96 [ 0.72, 1.28 ]
Total events: 51 (Pregabalin), 51 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
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Analysis 2.4. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 4 Seizure freedom.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 4 Seizure freedom
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 600 mg/d
Beydoun 2005 17/215 0/98 34.4 % 16.04 [ 0.97, 264.07 ]
Elger 2005 4/137 1/73 65.6 % 2.13 [ 0.24, 18.72 ]
Subtotal (95% CI) 352 171 100.0 % 6.92 [ 1.31, 36.70 ]
Total events: 21 (Pregabalin), 1 (Placebo)
Heterogeneity: Chi2 = 1.48, df = 1 (P = 0.22); I2 =32%
Test for overall effect: Z = 2.27 (P = 0.023)
2 Titrated dose of pregabalin (150 to 600 mg/d)
Baulac 2010 6/152 1/141 20.8 % 5.57 [ 0.68, 45.66 ]
Elger 2005 4/131 1/73 25.7 % 2.23 [ 0.25, 19.57 ]
Lee 2009 5/119 2/59 53.5 % 1.24 [ 0.25, 6.20 ]
Subtotal (95% CI) 402 273 100.0 % 2.39 [ 0.83, 6.89 ]
Total events: 15 (Pregabalin), 4 (Placebo)
Heterogeneity: Chi2 = 1.26, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.11)
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Analysis 2.5. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 5 Treatment
withdrawal for any reason.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 5 Treatment withdrawal for any reason
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 50 mg/d pregabalin
French 2003 10/88 13/100 100.0 % 0.87 [ 0.40, 1.89 ]
Subtotal (95% CI) 88 100 100.0 % 0.87 [ 0.40, 1.89 ]
Total events: 10 (Pregabalin), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
2 150 mg/d pregabalin
Arroyo 2004 11/99 13/97 51.9 % 0.83 [ 0.39, 1.76 ]
French 2003 7/88 13/100 48.1 % 0.61 [ 0.26, 1.46 ]
Subtotal (95% CI) 187 197 100.0 % 0.72 [ 0.41, 1.28 ]
Total events: 18 (Pregabalin), 26 (Placebo)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
3 300 mg/d pregabalin
French 2003 19/90 13/100 100.0 % 1.62 [ 0.85, 3.10 ]
Subtotal (95% CI) 90 100 100.0 % 1.62 [ 0.85, 3.10 ]
Total events: 19 (Pregabalin), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
4 600 mg/d pregabalin
Arroyo 2004 23/92 13/97 18.0 % 1.87 [ 1.01, 3.46 ]
Beydoun 2005 59/215 17/98 33.2 % 1.58 [ 0.98, 2.57 ]
Elger 2005 57/137 17/73 31.5 % 1.79 [ 1.13, 2.83 ]
French 2003 28/89 13/100 17.4 % 2.42 [ 1.34, 4.38 ]
Subtotal (95% CI) 533 368 100.0 % 1.84 [ 1.42, 2.40 ]
Total events: 167 (Pregabalin), 60 (Placebo)
Heterogeneity: Chi2 = 1.21, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 4.56 (P < 0.00001)
5 Titrated dose of pregabalin (150 to 600 mg/d)
Baulac 2010 46/152 35/141 59.7 % 1.22 [ 0.84, 1.77 ]
Elger 2005 31/131 17/73 35.9 % 1.02 [ 0.61, 1.71 ]
0.01 0.1 1 10 100
Favours pregabalin Favours placebo
(Continued . . . )
71Pregabalin add-on for drug-resistant focal epilepsy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lee 2009 10/119 2/59 4.4 % 2.48 [ 0.56, 10.95 ]
Subtotal (95% CI) 402 273 100.0 % 1.20 [ 0.89, 1.62 ]
Total events: 87 (Pregabalin), 54 (Placebo)
Heterogeneity: Chi2 = 1.32, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
6 165 mg/d pregabalin (controlled release)
French 2014 9/101 12/110 100.0 % 0.82 [ 0.36, 1.86 ]
Subtotal (95% CI) 101 110 100.0 % 0.82 [ 0.36, 1.86 ]
Total events: 9 (Pregabalin), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
7 330 mg/d pregabalin (controlled release)
French 2014 15/114 12/110 100.0 % 1.21 [ 0.59, 2.46 ]
Subtotal (95% CI) 114 110 100.0 % 1.21 [ 0.59, 2.46 ]
Total events: 15 (Pregabalin), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.61)
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Analysis 2.6. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 6 Treatment
withdrawal due to adverse effects.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 6 Treatment withdrawal due to adverse effects
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 50 mg/d pregabalin
French 2003 6/88 5/100 100.0 % 1.36 [ 0.43, 4.31 ]
Subtotal (95% CI) 88 100 100.0 % 1.36 [ 0.43, 4.31 ]
Total events: 6 (Pregabalin), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
2 150 mg/d pregabalin
Arroyo 2004 10/99 6/97 56.4 % 1.63 [ 0.62, 4.32 ]
French 2003 1/88 5/100 43.6 % 0.23 [ 0.03, 1.91 ]
Subtotal (95% CI) 187 197 100.0 % 1.02 [ 0.45, 2.32 ]
Total events: 11 (Pregabalin), 11 (Placebo)
Heterogeneity: Chi2 = 2.81, df = 1 (P = 0.09); I2 =64%
Test for overall effect: Z = 0.05 (P = 0.96)
3 300 mg/d pregabalin
French 2003 13/90 5/100 100.0 % 2.89 [ 1.07, 7.78 ]
Subtotal (95% CI) 90 100 100.0 % 2.89 [ 1.07, 7.78 ]
Total events: 13 (Pregabalin), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
4 600 mg/d pregabalin
Arroyo 2004 17/92 6/97 21.9 % 2.99 [ 1.23, 7.24 ]
Beydoun 2005 48/215 7/98 36.0 % 3.13 [ 1.47, 6.66 ]
Elger 2005 45/137 5/73 24.4 % 4.80 [ 1.99, 11.55 ]
French 2003 21/89 5/100 17.6 % 4.72 [ 1.86, 11.99 ]
Subtotal (95% CI) 533 368 100.0 % 3.78 [ 2.47, 5.81 ]
Total events: 131 (Pregabalin), 23 (Placebo)
Heterogeneity: Chi2 = 1.01, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 6.09 (P < 0.00001)
5 Titrated dose of pregabalin (150 to 600 mg/d)
Baulac 2010 24/152 10/141 59.4 % 2.23 [ 1.10, 4.49 ]
Elger 2005 16/131 5/73 36.8 % 1.78 [ 0.68, 4.67 ]
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Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lee 2009 7/119 0/59 3.8 % 7.50 [ 0.44, 129.13 ]
Subtotal (95% CI) 402 273 100.0 % 2.26 [ 1.30, 3.95 ]
Total events: 47 (Pregabalin), 15 (Placebo)
Heterogeneity: Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0039)
6 165 mg/d pregabalin (controlled release)
French 2014 3/101 3/110 100.0 % 1.09 [ 0.22, 5.27 ]
Subtotal (95% CI) 101 110 100.0 % 1.09 [ 0.22, 5.27 ]
Total events: 3 (Pregabalin), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.92)
7 330 mg/d pregabalin (controlled release)
French 2014 8/114 3/110 100.0 % 2.57 [ 0.70, 9.45 ]
Subtotal (95% CI) 114 110 100.0 % 2.57 [ 0.70, 9.45 ]
Total events: 8 (Pregabalin), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.15)
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Analysis 2.7. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 7 Ataxia.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 7 Ataxia
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 50 mg/d pregabalin
French 2003 3/88 3/100 100.0 % 1.14 [ 0.14, 9.00 ]
Subtotal (99% CI) 88 100 100.0 % 1.14 [ 0.14, 9.00 ]
Total events: 3 (Pregabalin), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
2 150 mg/d pregabalin
Arroyo 2004 2/99 3/97 51.9 % 0.65 [ 0.06, 6.66 ]
French 2003 9/88 3/100 48.1 % 3.41 [ 0.64, 18.21 ]
Subtotal (99% CI) 187 197 100.0 % 1.98 [ 0.56, 7.01 ]
Total events: 11 (Pregabalin), 6 (Placebo)
Heterogeneity: Chi2 = 2.21, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 1.39 (P = 0.16)
3 300 mg/d pregabalin
French 2003 9/90 3/100 100.0 % 3.33 [ 0.62, 17.81 ]
Subtotal (99% CI) 90 100 100.0 % 3.33 [ 0.62, 17.81 ]
Total events: 9 (Pregabalin), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
4 600 mg/d pregabalin
Arroyo 2004 16/92 3/97 16.3 % 5.62 [ 1.16, 27.21 ]
Beydoun 2005 48/215 6/98 46.0 % 3.65 [ 1.25, 10.63 ]
Elger 2005 29/137 3/73 21.9 % 5.15 [ 1.13, 23.48 ]
French 2003 13/89 3/100 15.8 % 4.87 [ 0.98, 24.28 ]
Subtotal (99% CI) 533 368 100.0 % 4.49 [ 2.25, 8.95 ]
Total events: 106 (Pregabalin), 15 (Placebo)
Heterogeneity: Chi2 = 0.46, df = 3 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 5.61 (P < 0.00001)
5 Titrated dose pregabalin (150 to 600 mg/d)
Baulac 2010 13/152 1/141 18.7 % 12.06 [ 0.85, 171.72 ]
Elger 2005 12/131 3/73 69.3 % 2.23 [ 0.44, 11.26 ]
Lee 2009 5/119 0/59 12.0 % 5.50 [ 0.13, 241.69 ]
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Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 402 273 100.0 % 4.46 [ 1.28, 15.48 ]
Total events: 30 (Pregabalin), 4 (Placebo)
Heterogeneity: Chi2 = 2.17, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 3.09 (P = 0.0020)
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Analysis 2.8. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 8 Dizziness.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 8 Dizziness
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 50 mg/d pregabalin
French 2003 8/88 9/100 100.0 % 1.01 [ 0.31, 3.33 ]
Subtotal (99% CI) 88 100 100.0 % 1.01 [ 0.31, 3.33 ]
Total events: 8 (Pregabalin), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
2 150 mg/d pregabalin
Arroyo 2004 19/99 8/97 49.0 % 2.33 [ 0.84, 6.46 ]
French 2003 14/88 9/100 51.0 % 1.77 [ 0.63, 4.97 ]
Subtotal (99% CI) 187 197 100.0 % 2.04 [ 0.99, 4.22 ]
Total events: 33 (Pregabalin), 17 (Placebo)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.011)
3 300 mg/d pregabalin
French 2003 28/90 9/100 100.0 % 3.46 [ 1.39, 8.62 ]
Subtotal (99% CI) 90 100 100.0 % 3.46 [ 1.39, 8.62 ]
Total events: 28 (Pregabalin), 9 (Placebo)
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Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Heterogeneity: not applicable
Test for overall effect: Z = 3.50 (P = 0.00047)
4 600 mg/d pregabalin
Arroyo 2004 24/92 8/97 18.0 % 3.16 [ 1.18, 8.45 ]
Beydoun 2005 88/215 14/98 44.4 % 2.87 [ 1.46, 5.61 ]
Elger 2005 59/137 6/73 18.1 % 5.24 [ 1.85, 14.81 ]
French 2003 38/89 9/100 19.6 % 4.74 [ 1.97, 11.41 ]
Subtotal (99% CI) 533 368 100.0 % 3.72 [ 2.42, 5.69 ]
Total events: 209 (Pregabalin), 37 (Placebo)
Heterogeneity: Chi2 = 2.41, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 7.92 (P < 0.00001)
5 Titrated dose of pregabalin (150 to 600 mg/d pregabalin)
Baulac 2010 38/152 13/141 46.2 % 2.71 [ 1.25, 5.86 ]
Elger 2005 32/131 6/73 26.4 % 2.97 [ 1.01, 8.77 ]
Lee 2009 46/119 6/59 27.5 % 3.80 [ 1.34, 10.76 ]
Subtotal (99% CI) 402 273 100.0 % 3.08 [ 1.80, 5.28 ]
Total events: 116 (Pregabalin), 25 (Placebo)
Heterogeneity: Chi2 = 0.46, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 5.37 (P < 0.00001)
6 165 mg/d pregabalin (controlled release)
French 2014 11/101 2/110 100.0 % 5.99 [ 0.85, 42.02 ]
Subtotal (99% CI) 101 110 100.0 % 5.99 [ 0.85, 42.02 ]
Total events: 11 (Pregabalin), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
7 330 mg/d pregabalin (controlled release)
French 2014 11/114 2/110 100.0 % 5.31 [ 0.76, 37.30 ]
Subtotal (99% CI) 114 110 100.0 % 5.31 [ 0.76, 37.30 ]
Total events: 11 (Pregabalin), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.027)
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Analysis 2.9. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 9 Fatigue.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 9 Fatigue
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 50 mg/d pregabalin
French 2003 5/88 8/100 100.0 % 0.71 [ 0.17, 2.94 ]
Subtotal (99% CI) 88 100 100.0 % 0.71 [ 0.17, 2.94 ]
Total events: 5 (Pregabalin), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
2 150 mg/d pregabalin
Arroyo 2004 13/99 11/97 59.7 % 1.16 [ 0.43, 3.11 ]
French 2003 7/88 8/100 40.3 % 0.99 [ 0.28, 3.57 ]
Subtotal (99% CI) 187 197 100.0 % 1.09 [ 0.50, 2.39 ]
Total events: 20 (Pregabalin), 19 (Placebo)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
3 300 mg/d pregabalin
French 2003 11/90 8/100 100.0 % 1.53 [ 0.49, 4.76 ]
Subtotal (99% CI) 90 100 100.0 % 1.53 [ 0.49, 4.76 ]
Total events: 11 (Pregabalin), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
4 600 mg/d pregabalin
Arroyo 2004 13/92 11/97 28.1 % 1.25 [ 0.46, 3.34 ]
Beydoun 2005 27/215 5/98 18.0 % 2.46 [ 0.73, 8.29 ]
Elger 2005 25/137 10/73 34.2 % 1.33 [ 0.55, 3.24 ]
French 2003 9/89 8/100 19.7 % 1.26 [ 0.38, 4.17 ]
Subtotal (99% CI) 533 368 100.0 % 1.50 [ 0.89, 2.52 ]
Total events: 74 (Pregabalin), 34 (Placebo)
Heterogeneity: Chi2 = 1.59, df = 3 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.046)
5 Titrated dose of pregabalin (150 to 600 mg/d)
Baulac 2010 26/152 24/141 59.6 % 1.00 [ 0.52, 1.95 ]
Elger 2005 22/131 10/73 30.8 % 1.23 [ 0.49, 3.04 ]
Lee 2009 11/119 3/59 9.6 % 1.82 [ 0.36, 9.25 ]
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Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 402 273 100.0 % 1.15 [ 0.69, 1.91 ]
Total events: 59 (Pregabalin), 37 (Placebo)
Heterogeneity: Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
6 165 mg/d pregabalin (controlled release)
French 2014 3/101 1/110 100.0 % 3.27 [ 0.17, 62.62 ]
Subtotal (99% CI) 101 110 100.0 % 3.27 [ 0.17, 62.62 ]
Total events: 3 (Pregabalin), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
7 330 mg/d pregabalin (controlled release)
French 2014 6/114 1/110 100.0 % 5.79 [ 0.37, 91.55 ]
Subtotal (99% CI) 114 110 100.0 % 5.79 [ 0.37, 91.55 ]
Total events: 6 (Pregabalin), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
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Analysis 2.10. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 10 Headache.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 10 Headache
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 50 mg/d pregabalin
French 2003 6/88 13/100 100.0 % 0.52 [ 0.16, 1.77 ]
Subtotal (99% CI) 88 100 100.0 % 0.52 [ 0.16, 1.77 ]
Total events: 6 (Pregabalin), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
2 150 mg/d pregabalin
Arroyo 2004 6/99 15/97 55.5 % 0.39 [ 0.12, 1.29 ]
French 2003 8/88 13/100 44.5 % 0.70 [ 0.23, 2.09 ]
Subtotal (99% CI) 187 197 100.0 % 0.53 [ 0.24, 1.17 ]
Total events: 14 (Pregabalin), 28 (Placebo)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.040)
3 300 mg/d pregabalin
French 2003 5/90 13/100 100.0 % 0.43 [ 0.12, 1.57 ]
Subtotal (99% CI) 90 100 100.0 % 0.43 [ 0.12, 1.57 ]
Total events: 5 (Pregabalin), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.093)
4 600 mg/d pregabalin
Arroyo 2004 11/92 15/97 39.2 % 0.77 [ 0.30, 2.00 ]
Elger 2005 10/137 8/73 28.0 % 0.67 [ 0.21, 2.13 ]
French 2003 5/89 13/100 32.8 % 0.43 [ 0.12, 1.59 ]
Subtotal (99% CI) 318 270 100.0 % 0.63 [ 0.33, 1.19 ]
Total events: 26 (Pregabalin), 36 (Placebo)
Heterogeneity: Chi2 = 0.88, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
5 Titrated dose of pregabalin (150 to 600 mg/d)
Baulac 2010 18/152 28/141 59.7 % 0.60 [ 0.29, 1.22 ]
Elger 2005 18/131 8/73 21.1 % 1.25 [ 0.45, 3.50 ]
Lee 2009 9/119 7/59 19.2 % 0.64 [ 0.19, 2.18 ]
Subtotal (99% CI) 402 273 100.0 % 0.74 [ 0.44, 1.25 ]
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Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Total events: 45 (Pregabalin), 43 (Placebo)
Heterogeneity: Chi2 = 2.45, df = 2 (P = 0.29); I2 =18%
Test for overall effect: Z = 1.46 (P = 0.14)
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Analysis 2.11. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 11 Nausea.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 11 Nausea
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 150 mg/d pregabalin
Arroyo 2004 8/99 6/97 100.0 % 1.31 [ 0.34, 5.00 ]
Subtotal (99% CI) 99 97 100.0 % 1.31 [ 0.34, 5.00 ]
Total events: 8 (Pregabalin), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
2 600 mg/d pregabalin
Arroyo 2004 5/92 6/97 35.0 % 0.88 [ 0.19, 3.99 ]
Beydoun 2005 11/215 6/98 49.4 % 0.84 [ 0.23, 2.97 ]
Elger 2005 11/137 2/73 15.6 % 2.93 [ 0.42, 20.49 ]
Subtotal (99% CI) 444 268 100.0 % 1.18 [ 0.51, 2.75 ]
Total events: 27 (Pregabalin), 14 (Placebo)
Heterogeneity: Chi2 = 2.19, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 0.50 (P = 0.62)
3 Titrated dose of pregabalin (150 to 600 mg/d)
Elger 2005 4/131 2/73 100.0 % 1.11 [ 0.12, 10.05 ]
Subtotal (99% CI) 131 73 100.0 % 1.11 [ 0.12, 10.05 ]
Total events: 4 (Pregabalin), 2 (Placebo)
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Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
4 165 mg/d pregabalin (controlled release)
French 2014 3/101 1/110 100.0 % 3.27 [ 0.17, 62.62 ]
Subtotal (99% CI) 101 110 100.0 % 3.27 [ 0.17, 62.62 ]
Total events: 3 (Pregabalin), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
5 330 mg/d pregabalin (controlled release)
French 2014 1/114 1/110 100.0 % 0.96 [ 0.03, 36.26 ]
Subtotal (99% CI) 114 110 100.0 % 0.96 [ 0.03, 36.26 ]
Total events: 1 (Pregabalin), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
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Analysis 2.12. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 12 Somnolence.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 12 Somnolence
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 50 mg/d pregabalin
French 2003 9/88 11/100 100.0 % 0.93 [ 0.31, 2.78 ]
Subtotal (99% CI) 88 100 100.0 % 0.93 [ 0.31, 2.78 ]
Total events: 9 (Pregabalin), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
2 150 mg/d pregabalin
Arroyo 2004 6/99 7/97 40.7 % 0.84 [ 0.21, 3.35 ]
French 2003 15/88 11/100 59.3 % 1.55 [ 0.60, 4.01 ]
Subtotal (99% CI) 187 197 100.0 % 1.26 [ 0.58, 2.74 ]
Total events: 21 (Pregabalin), 18 (Placebo)
Heterogeneity: Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
3 300 mg/d pregabalin
French 2003 16/90 11/100 100.0 % 1.62 [ 0.63, 4.12 ]
Subtotal (99% CI) 90 100 100.0 % 1.62 [ 0.63, 4.12 ]
Total events: 16 (Pregabalin), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
4 600 mg/d pregabalin
Arroyo 2004 27/92 7/97 16.4 % 4.07 [ 1.46, 11.35 ]
Beydoun 2005 57/215 12/98 39.7 % 2.17 [ 1.02, 4.61 ]
Elger 2005 24/137 6/73 18.9 % 2.13 [ 0.70, 6.50 ]
French 2003 25/89 11/100 25.0 % 2.55 [ 1.09, 5.99 ]
Subtotal (99% CI) 533 368 100.0 % 2.57 [ 1.64, 4.03 ]
Total events: 133 (Pregabalin), 36 (Placebo)
Heterogeneity: Chi2 = 1.86, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 5.39 (P < 0.00001)
5 Titrated dose of pregabalin
Baulac 2010 30/152 15/141 57.0 % 1.86 [ 0.87, 3.95 ]
Elger 2005 25/131 6/73 28.2 % 2.32 [ 0.77, 7.04 ]
Lee 2009 26/119 3/59 14.7 % 4.30 [ 0.94, 19.57 ]
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Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 402 273 100.0 % 2.35 [ 1.31, 4.19 ]
Total events: 81 (Pregabalin), 24 (Placebo)
Heterogeneity: Chi2 = 1.70, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.79 (P = 0.00015)
6 165 mg/d pregabalin (controlled release)
French 2014 4/101 2/110 100.0 % 2.18 [ 0.24, 19.70 ]
Subtotal (99% CI) 101 110 100.0 % 2.18 [ 0.24, 19.70 ]
Total events: 4 (Pregabalin), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
7 330 mg/d pregabalin (controlled release)
French 2014 6/114 2/110 100.0 % 2.89 [ 0.36, 23.05 ]
Subtotal (99% CI) 114 110 100.0 % 2.89 [ 0.36, 23.05 ]
Total events: 6 (Pregabalin), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
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Analysis 2.13. Comparison 2 Pregabalin versus placebo - subgroup analysis, Outcome 13 Weight gain.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 2 Pregabalin versus placebo - subgroup analysis
Outcome: 13 Weight gain
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 50 mg/d pregabalin
French 2003 1/88 0/100 100.0 % 3.40 [ 0.05, 224.69 ]
Subtotal (99% CI) 88 100 100.0 % 3.40 [ 0.05, 224.69 ]
Total events: 1 (Pregabalin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
2 150 mg/d pregabalin
Arroyo 2004 7/99 2/97 81.2 % 3.43 [ 0.45, 26.17 ]
French 2003 2/88 0/100 18.8 % 5.67 [ 0.11, 301.50 ]
Subtotal (99% CI) 187 197 100.0 % 3.85 [ 0.64, 23.35 ]
Total events: 9 (Pregabalin), 2 (Placebo)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.054)
3 300 mg/d pregabalin
French 2003 6/90 0/100 100.0 % 14.43 [ 0.34, 620.87 ]
Subtotal (99% CI) 90 100 100.0 % 14.43 [ 0.34, 620.87 ]
Total events: 6 (Pregabalin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
4 600 mg/d pregabalin
Arroyo 2004 13/92 2/97 16.7 % 6.85 [ 1.00, 46.76 ]
Beydoun 2005 38/215 2/98 23.5 % 8.66 [ 1.37, 54.65 ]
Elger 2005 28/137 5/73 55.8 % 2.98 [ 0.90, 9.84 ]
French 2003 11/89 0/100 4.0 % 25.81 [ 0.64, 1046.44 ]
Subtotal (99% CI) 533 368 100.0 % 5.88 [ 2.52, 13.73 ]
Total events: 90 (Pregabalin), 9 (Placebo)
Heterogeneity: Chi2 = 3.54, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 5.39 (P < 0.00001)
5 Titrated dose of pregabalin (150 to 600 mg/d pregabalin)
Baulac 2010 14/152 2/141 18.6 % 6.49 [ 0.95, 44.46 ]
Elger 2005 25/131 5/73 57.5 % 2.79 [ 0.84, 9.29 ]
Lee 2009 14/119 2/59 23.9 % 3.47 [ 0.52, 23.28 ]
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(. . . Continued)
Study or subgroup Pregabalin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (99% CI) 402 273 100.0 % 3.64 [ 1.49, 8.87 ]
Total events: 53 (Pregabalin), 9 (Placebo)
Heterogeneity: Chi2 = 0.93, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.74 (P = 0.00019)
6 165 mg/d pregabalin (controlled release)
French 2014 1/101 0/110 100.0 % 3.26 [ 0.05, 215.86 ]
Subtotal (99% CI) 101 110 100.0 % 3.26 [ 0.05, 215.86 ]
Total events: 1 (Pregabalin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
7 330 mg/d pregabalin (controlled release)
French 2014 7/114 0/110 100.0 % 14.48 [ 0.34, 613.54 ]
Subtotal (99% CI) 114 110 100.0 % 14.48 [ 0.34, 613.54 ]
Total events: 7 (Pregabalin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
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Analysis 3.1. Comparison 3 Pregabalin versus active comparator, Outcome 1 50% or greater reduction in
seizure frequency.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 1 50% or greater reduction in seizure frequency
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Baulac 2010 54/152 34/141 18.7 % 1.47 [ 1.03, 2.12 ]
French 2016 134/242 140/242 41.2 % 0.96 [ 0.82, 1.12 ]
Zaccara 2014 130/254 139/255 40.1 % 0.94 [ 0.80, 1.11 ]
Total (95% CI) 648 638 100.0 % 1.03 [ 0.85, 1.25 ]
Total events: 318 (Pregabalin), 313 (Active comparator)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.19, df = 2 (P = 0.07); I2 =61%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Pregabalin versus active comparator, Outcome 2 50% or greater reduction in
seizure frequency - best-case analysis.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 2 50% or greater reduction in seizure frequency - best-case analysis
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Baulac 2010 100/152 34/141 27.7 % 2.73 [ 1.99, 3.74 ]
French 2016 188/242 140/242 36.4 % 1.34 [ 1.18, 1.52 ]
Zaccara 2014 176/254 139/255 35.9 % 1.27 [ 1.11, 1.46 ]
Total (95% CI) 648 638 100.0 % 1.60 [ 1.17, 2.19 ]
Total events: 464 (Pregabalin), 313 (Active comparator)
Heterogeneity: Tau2 = 0.06; Chi2 = 19.54, df = 2 (P = 0.00006); I2 =90%
Test for overall effect: Z = 2.98 (P = 0.0029)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Pregabalin versus active comparator, Outcome 3 50% or greater reduction in
seizure frequency - worst-case analysis.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 3 50% or greater reduction in seizure frequency - worst-case analysis
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Baulac 2010 54/152 74/141 16.4 % 0.68 [ 0.52, 0.88 ]
French 2016 134/242 209/242 44.5 % 0.64 [ 0.57, 0.73 ]
Zaccara 2014 130/254 184/255 39.1 % 0.71 [ 0.62, 0.82 ]
Total (95% CI) 648 638 100.0 % 0.67 [ 0.62, 0.74 ]
Total events: 318 (Pregabalin), 467 (Active comparator)
Heterogeneity: Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 8.63 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Pregabalin versus active comparator, Outcome 4 Seizure freedom.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 4 Seizure freedom
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Baulac 2010 6/152 4/141 9.9 % 1.39 [ 0.40, 4.83 ]
Zaccara 2014 19/254 38/255 90.1 % 0.50 [ 0.30, 0.85 ]
Total (95% CI) 406 396 100.0 % 0.59 [ 0.37, 0.95 ]
Total events: 25 (Pregabalin), 42 (Active comparator)
Heterogeneity: Chi2 = 2.19, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 2.19 (P = 0.029)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Pregabalin versus active comparator, Outcome 5 Treatment withdrawal for any
reason.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 5 Treatment withdrawal for any reason
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Baulac 2010 46/152 40/141 26.7 % 1.07 [ 0.75, 1.52 ]
French 2016 54/242 69/242 44.4 % 0.78 [ 0.57, 1.07 ]
Zaccara 2014 46/254 45/255 28.9 % 1.03 [ 0.71, 1.49 ]
Total (95% CI) 648 638 100.0 % 0.93 [ 0.76, 1.13 ]
Total events: 146 (Pregabalin), 154 (Active comparator)
Heterogeneity: Chi2 = 2.04, df = 2 (P = 0.36); I2 =2%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours pregabalin Favours active comparator
90Pregabalin add-on for drug-resistant focal epilepsy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.6. Comparison 3 Pregabalin versus active comparator, Outcome 6 Treatment withdrawal due to
adverse effects.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 6 Treatment withdrawal due to adverse effects
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Baulac 2010 24/152 25/141 47.2 % 0.89 [ 0.53, 1.48 ]
French 2016 16/242 15/242 27.3 % 1.07 [ 0.54, 2.11 ]
Zaccara 2014 18/254 14/255 25.4 % 1.29 [ 0.66, 2.54 ]
Total (95% CI) 648 638 100.0 % 1.04 [ 0.73, 1.48 ]
Total events: 58 (Pregabalin), 54 (Active comparator)
Heterogeneity: Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Pregabalin versus active comparator, Outcome 7 Ataxia.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 7 Ataxia
Study or subgroup Pregabalin Active Comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Baulac 2010 13/152 7/141 100.0 % 1.72 [ 0.54, 5.55 ]
Total (99% CI) 152 141 100.0 % 1.72 [ 0.54, 5.55 ]
Total events: 13 (Pregabalin), 7 (Active Comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Pregabalin versus active comparator, Outcome 8 Dizziness.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 8 Dizziness
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Baulac 2010 38/152 12/141 29.3 % 2.94 [ 1.32, 6.52 ]
French 2016 22/242 20/242 30.5 % 1.10 [ 0.51, 2.35 ]
Zaccara 2014 56/254 39/255 40.2 % 1.44 [ 0.89, 2.34 ]
Total (99% CI) 648 638 100.0 % 1.64 [ 0.85, 3.16 ]
Total events: 116 (Pregabalin), 71 (Active comparator)
Heterogeneity: Tau2 = 0.13; Chi2 = 5.75, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Pregabalin versus active comparator, Outcome 9 Fatigue.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 9 Fatigue
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Baulac 2010 26/152 14/141 100.0 % 1.72 [ 0.77, 3.83 ]
Total (99% CI) 152 141 100.0 % 1.72 [ 0.77, 3.83 ]
Total events: 26 (Pregabalin), 14 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 Pregabalin versus active comparator, Outcome 10 Headache.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 10 Headache
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Baulac 2010 18/152 32/141 34.3 % 0.52 [ 0.26, 1.05 ]
French 2016 17/242 20/242 30.4 % 0.85 [ 0.38, 1.92 ]
Zaccara 2014 30/254 24/255 35.3 % 1.25 [ 0.64, 2.45 ]
Total (99% CI) 648 638 100.0 % 0.83 [ 0.41, 1.65 ]
Total events: 65 (Pregabalin), 76 (Active comparator)
Heterogeneity: Tau2 = 0.14; Chi2 = 5.50, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 0.71 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Pregabalin versus active comparator, Outcome 11 Nausea.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 11 Nausea
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Zaccara 2014 3/254 15/255 100.0 % 0.20 [ 0.04, 1.01 ]
Total (99% CI) 254 255 100.0 % 0.20 [ 0.04, 1.01 ]
Total events: 3 (Pregabalin), 15 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
Test for subgroup differences: Not applicable
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Analysis 3.12. Comparison 3 Pregabalin versus active comparator, Outcome 12 Somnolence.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 12 Somnolence
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Baulac 2010 30/152 15/141 12.7 % 1.86 [ 0.87, 3.95 ]
French 2016 34/242 34/242 27.8 % 1.00 [ 0.56, 1.78 ]
Zaccara 2014 79/254 73/255 59.5 % 1.09 [ 0.77, 1.54 ]
Total (99% CI) 648 638 100.0 % 1.16 [ 0.88, 1.53 ]
Total events: 143 (Pregabalin), 122 (Active comparator)
Heterogeneity: Chi2 = 3.22, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 Pregabalin versus active comparator, Outcome 13 Weight gain.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 3 Pregabalin versus active comparator
Outcome: 13 Weight gain
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Baulac 2010 14/152 3/141 25.8 % 4.33 [ 0.86, 21.68 ]
French 2016 19/242 13/242 41.1 % 1.46 [ 0.60, 3.58 ]
Zaccara 2014 24/254 5/255 33.0 % 4.82 [ 1.39, 16.74 ]
Total (99% CI) 648 638 100.0 % 2.87 [ 0.94, 8.75 ]
Total events: 57 (Pregabalin), 21 (Active comparator)
Heterogeneity: Tau2 = 0.33; Chi2 = 4.99, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Pregabalin versus active comparator - subgroup analysis, Outcome 1 50% or
greater reduction in seizure frequency.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 4 Pregabalin versus active comparator - subgroup analysis
Outcome: 1 50% or greater reduction in seizure frequency
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pregabalin versus lamotrigine
Baulac 2010 54/152 34/141 100.0 % 1.47 [ 1.03, 2.12 ]
Subtotal (95% CI) 152 141 100.0 % 1.47 [ 1.03, 2.12 ]
Total events: 54 (Pregabalin), 34 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.036)
2 Pregabalin versus levetiracetam
Zaccara 2014 130/254 139/255 100.0 % 0.94 [ 0.80, 1.11 ]
Subtotal (95% CI) 254 255 100.0 % 0.94 [ 0.80, 1.11 ]
Total events: 130 (Pregabalin), 139 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
3 Pregabalin versus gabapentin
French 2016 134/242 140/242 100.0 % 0.96 [ 0.82, 1.12 ]
Subtotal (95% CI) 242 242 100.0 % 0.96 [ 0.82, 1.12 ]
Total events: 134 (Pregabalin), 140 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 5.19, df = 2 (P = 0.07), I2 =61%
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Analysis 4.2. Comparison 4 Pregabalin versus active comparator - subgroup analysis, Outcome 2 50% or
greater reduction in seizure frequency - best-case analysis.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 4 Pregabalin versus active comparator - subgroup analysis
Outcome: 2 50% or greater reduction in seizure frequency - best-case analysis
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pregabalin versus lamotrigine
Baulac 2010 100/152 34/141 100.0 % 2.73 [ 1.99, 3.74 ]
Subtotal (95% CI) 152 141 100.0 % 2.73 [ 1.99, 3.74 ]
Total events: 100 (Pregabalin), 34 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 6.26 (P < 0.00001)
2 Pregabalin versus levetiracetam
Zaccara 2014 176/254 139/255 100.0 % 1.27 [ 1.11, 1.46 ]
Subtotal (95% CI) 254 255 100.0 % 1.27 [ 1.11, 1.46 ]
Total events: 176 (Pregabalin), 139 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 3.39 (P = 0.00071)
3 Pregabalin versus gabapentin
French 2016 188/242 140/242 100.0 % 1.34 [ 1.18, 1.52 ]
Subtotal (95% CI) 242 242 100.0 % 1.34 [ 1.18, 1.52 ]
Total events: 188 (Pregabalin), 140 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 4.55 (P < 0.00001)
Test for subgroup differences: Chi2 = 19.54, df = 2 (P = 0.00), I2 =90%
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Analysis 4.3. Comparison 4 Pregabalin versus active comparator - subgroup analysis, Outcome 3 50% or
greater reduction in seizure frequency - worst-case analysis.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 4 Pregabalin versus active comparator - subgroup analysis
Outcome: 3 50% or greater reduction in seizure frequency - worst-case analysis
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pregabalin versus lamotrigine
Baulac 2010 54/152 74/141 100.0 % 0.68 [ 0.52, 0.88 ]
Subtotal (95% CI) 152 141 100.0 % 0.68 [ 0.52, 0.88 ]
Total events: 54 (Pregabalin), 74 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0040)
2 Pregabalin versus levetiracetam
Zaccara 2014 130/254 184/255 100.0 % 0.71 [ 0.62, 0.82 ]
Subtotal (95% CI) 254 255 100.0 % 0.71 [ 0.62, 0.82 ]
Total events: 130 (Pregabalin), 184 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 4.73 (P < 0.00001)
3 Pregabalin versus gabapentin
French 2016 134/242 209/242 100.0 % 0.64 [ 0.57, 0.73 ]
Subtotal (95% CI) 242 242 100.0 % 0.64 [ 0.57, 0.73 ]
Total events: 134 (Pregabalin), 209 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 7.04 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.11, df = 2 (P = 0.57), I2 =0.0%
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Analysis 4.4. Comparison 4 Pregabalin versus active comparator - subgroup analysis, Outcome 4 Seizure
freedom.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 4 Pregabalin versus active comparator - subgroup analysis
Outcome: 4 Seizure freedom
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pregabalin versus lamotrigine
Baulac 2010 6/152 4/141 100.0 % 1.39 [ 0.40, 4.83 ]
Subtotal (95% CI) 152 141 100.0 % 1.39 [ 0.40, 4.83 ]
Total events: 6 (Pregabalin), 4 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
2 Pregabalin versus levetiracetam
Zaccara 2014 19/254 38/255 100.0 % 0.50 [ 0.30, 0.85 ]
Subtotal (95% CI) 254 255 100.0 % 0.50 [ 0.30, 0.85 ]
Total events: 19 (Pregabalin), 38 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P = 0.0097)
Test for subgroup differences: Chi2 = 2.19, df = 1 (P = 0.14), I2 =54%
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Analysis 4.5. Comparison 4 Pregabalin versus active comparator - subgroup analysis, Outcome 5
Treatment withdrawal for any reason.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 4 Pregabalin versus active comparator - subgroup analysis
Outcome: 5 Treatment withdrawal for any reason
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pregabalin versus lamotrigine
Baulac 2010 46/152 40/141 100.0 % 1.07 [ 0.75, 1.52 ]
Subtotal (95% CI) 152 141 100.0 % 1.07 [ 0.75, 1.52 ]
Total events: 46 (Pregabalin), 40 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 Pregabalin versus levetiracetam
Zaccara 2014 46/254 45/255 100.0 % 1.03 [ 0.71, 1.49 ]
Subtotal (95% CI) 254 255 100.0 % 1.03 [ 0.71, 1.49 ]
Total events: 46 (Pregabalin), 45 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
3 Pregabalin versus gabapentin
French 2016 54/242 69/242 100.0 % 0.78 [ 0.57, 1.07 ]
Subtotal (95% CI) 242 242 100.0 % 0.78 [ 0.57, 1.07 ]
Total events: 54 (Pregabalin), 69 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Chi2 = 2.04, df = 2 (P = 0.36), I2 =2%
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Analysis 4.6. Comparison 4 Pregabalin versus active comparator - subgroup analysis, Outcome 6
Treatment withdrawal due to adverse effects.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 4 Pregabalin versus active comparator - subgroup analysis
Outcome: 6 Treatment withdrawal due to adverse effects
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pregabalin versus lamotrigine
Baulac 2010 24/152 25/141 100.0 % 0.89 [ 0.53, 1.48 ]
Subtotal (95% CI) 152 141 100.0 % 0.89 [ 0.53, 1.48 ]
Total events: 24 (Pregabalin), 25 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
2 Pregabalin versus levetiracetam
Zaccara 2014 18/254 14/255 100.0 % 1.29 [ 0.66, 2.54 ]
Subtotal (95% CI) 254 255 100.0 % 1.29 [ 0.66, 2.54 ]
Total events: 18 (Pregabalin), 14 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
3 Pregabalin versus gabapentin
French 2016 16/242 15/242 100.0 % 1.07 [ 0.54, 2.11 ]
Subtotal (95% CI) 242 242 100.0 % 1.07 [ 0.54, 2.11 ]
Total events: 16 (Pregabalin), 15 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 0.75, df = 2 (P = 0.69), I2 =0.0%
0.01 0.1 1 10 100
Favours pregabalin Favours active comparator
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Analysis 4.7. Comparison 4 Pregabalin versus active comparator - subgroup analysis, Outcome 7 Dizziness.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 4 Pregabalin versus active comparator - subgroup analysis
Outcome: 7 Dizziness
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Pregabalin versus lamotrigine
Baulac 2010 38/152 12/141 100.0 % 2.94 [ 1.32, 6.52 ]
Subtotal (99% CI) 152 141 100.0 % 2.94 [ 1.32, 6.52 ]
Total events: 38 (Pregabalin), 12 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 3.48 (P = 0.00050)
2 Pregabalin versus levetiracetam
Zaccara 2014 56/254 39/255 100.0 % 1.44 [ 0.89, 2.34 ]
Subtotal (99% CI) 254 255 100.0 % 1.44 [ 0.89, 2.34 ]
Total events: 56 (Pregabalin), 39 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.053)
3 Pregabalin versus gabapentin
French 2016 22/242 20/242 100.0 % 1.10 [ 0.51, 2.35 ]
Subtotal (99% CI) 242 242 100.0 % 1.10 [ 0.51, 2.35 ]
Total events: 22 (Pregabalin), 20 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Chi2 = 5.75, df = 2 (P = 0.06), I2 =65%
0.01 0.1 1 10 100
Favours pregabalin Favours active comparator
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Analysis 4.8. Comparison 4 Pregabalin versus active comparator - subgroup analysis, Outcome 8 Headache.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 4 Pregabalin versus active comparator - subgroup analysis
Outcome: 8 Headache
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Pregabalin versus lamotrigine
Baulac 2010 18/152 32/141 100.0 % 0.52 [ 0.26, 1.05 ]
Subtotal (99% CI) 152 141 100.0 % 0.52 [ 0.26, 1.05 ]
Total events: 18 (Pregabalin), 32 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
2 Pregabalin versus levetiracetam
Zaccara 2014 30/254 24/255 100.0 % 1.25 [ 0.64, 2.45 ]
Subtotal (99% CI) 254 255 100.0 % 1.25 [ 0.64, 2.45 ]
Total events: 30 (Pregabalin), 24 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
3 Pregabalin versus gabapentin
French 2016 17/242 20/242 100.0 % 0.85 [ 0.38, 1.92 ]
Subtotal (99% CI) 242 242 100.0 % 0.85 [ 0.38, 1.92 ]
Total events: 17 (Pregabalin), 20 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Chi2 = 5.50, df = 2 (P = 0.06), I2 =64%
0.01 0.1 1 10 100
Favours pregabalin Favours active comparator
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Analysis 4.9. Comparison 4 Pregabalin versus active comparator - subgroup analysis, Outcome 9 Nausea.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 4 Pregabalin versus active comparator - subgroup analysis
Outcome: 9 Nausea
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Pregabalin versus levetiracetam
Zaccara 2014 3/254 15/255 100.0 % 0.20 [ 0.04, 1.01 ]
Subtotal (99% CI) 254 255 100.0 % 0.20 [ 0.04, 1.01 ]
Total events: 3 (Pregabalin), 15 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pregabalin Favours active comparator
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Analysis 4.10. Comparison 4 Pregabalin versus active comparator - subgroup analysis, Outcome 10
Somnolence.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 4 Pregabalin versus active comparator - subgroup analysis
Outcome: 10 Somnolence
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Pregabalin versus lamotrigine
Baulac 2010 30/152 14/141 100.0 % 1.99 [ 0.91, 4.33 ]
Subtotal (99% CI) 152 141 100.0 % 1.99 [ 0.91, 4.33 ]
Total events: 30 (Pregabalin), 14 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.023)
2 Pregabalin versus levetiracetam
Zaccara 2014 79/254 73/255 100.0 % 1.09 [ 0.77, 1.54 ]
Subtotal (99% CI) 254 255 100.0 % 1.09 [ 0.77, 1.54 ]
Total events: 79 (Pregabalin), 73 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 Pregabalin versus gabapentin
French 2016 34/242 34/242 100.0 % 1.00 [ 0.56, 1.78 ]
Subtotal (99% CI) 242 242 100.0 % 1.00 [ 0.56, 1.78 ]
Total events: 34 (Pregabalin), 34 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 3.85, df = 2 (P = 0.15), I2 =48%
0.01 0.1 1 10 100
Favours pregabalin Favours active comparator
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Analysis 4.11. Comparison 4 Pregabalin versus active comparator - subgroup analysis, Outcome 11 Weight
gain.
Review: Pregabalin add-on for drug-resistant focal epilepsy
Comparison: 4 Pregabalin versus active comparator - subgroup analysis
Outcome: 11 Weight gain
Study or subgroup Pregabalin Active comparator Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Pregabalin versus lamotrigine
Baulac 2010 14/152 3/141 100.0 % 4.33 [ 0.86, 21.68 ]
Subtotal (99% CI) 152 141 100.0 % 4.33 [ 0.86, 21.68 ]
Total events: 14 (Pregabalin), 3 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
2 Pregabalin versus levetiracetam
Zaccara 2014 24/254 5/255 100.0 % 4.82 [ 1.39, 16.74 ]
Subtotal (99% CI) 254 255 100.0 % 4.82 [ 1.39, 16.74 ]
Total events: 24 (Pregabalin), 5 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 3.25 (P = 0.0011)
3 Pregabalin versus gabapentin
French 2016 19/242 13/242 100.0 % 1.46 [ 0.60, 3.58 ]
Subtotal (99% CI) 242 242 100.0 % 1.46 [ 0.60, 3.58 ]
Total events: 19 (Pregabalin), 13 (Active comparator)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Chi2 = 4.99, df = 2 (P = 0.08), I2 =60%
0.01 0.1 1 10 100
Favours pregabalin Favours active comparator
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A P P E N D I C E S
Appendix 1. Cochrane Register of Studies (CRS Web) search strategy
1. MESH DESCRIPTOR Pregabalin EXPLODE ALL AND CENTRAL:TARGET
2. (lyrica OR pregabalin*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
3. #1 OR #2
4. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
5. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
6. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
7. #4 OR #5 OR #6 AND CENTRAL:TARGET
8. #3 AND #7
9. (monotherap* NOT (adjunct* OR “add-on” OR “add on” OR adjuvant* OR combination* OR polytherap*)):TI ANDCENTRAL:
TARGET
10. #8 NOT #9
11. >06/09/2016:CRSINCENTRAL AND CENTRAL:TARGET
12. #10 AND #11
Appendix 2. MEDLINE (Ovid) search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials, published in Lefebvre 2011.
1. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
2. clinical trials as topic.sh.
3. trial.ti.
4. 1 or 2 or 3
5. exp animals/ not humans.sh.
6. 4 not 5
7. exp Epilepsy/
8. exp Seizures/
9. (epilep$ or seizure$ or convuls$).tw.
10. 7 or 8 or 9
11. exp Pregabalin/ or (pregabalin$ or lyrica).tw.
12. 6 and 10 and 11
13. (monotherap$ not (adjunct$ or “add-on” or “add on” or adjuvant$ or combination$ or polytherap$)).ti.
14. 12 not 13
15. limit 14 to ed=20160906-20180705
16. 14 not (1$ or 2$).ed.
17. 16 and (2016$ or 2017$ or 2018$).dt.
18. 15 or 17
19. remove duplicates from 18
Appendix 3. ClinicalTrials.gov search strategy
Interventional Studies | Epilepsies, Partial | Pregabalin
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Appendix 4. WHO ICTRP search strategy
Condition: Partial epilepsy OR Focal epilepsy
Intervention: Lyrica OR Pregabalin
Phases: 2, 3, 4
WH A T ’ S N E W
Date Event Description
5 July 2018 New citation required but conclusions have not changed Conclusions remain the same.
5 July 2018 New search has been performed Searches updated 5 July 2018; three new studies (French
2014, French 2016 and Zaccara 2014) have been added
to the review.
The term ’partial’ has been replaced by ’focal’, in accor-
dance with the most recent classification of epilepsies of
the International League Against Epilepsy (Scheffer 2017)
.
H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 1, 2008
Date Event Description
9 January 2014 New search has been performed Searches updated 9 January 2014; one previously on-
going study, Bali 2012, has been added to excluded
studies (Taghdiri 2015).
9 January 2014 New citation required but conclusions have not
changed
Conclusions remain the same.
12 June 2012 New search has been performed Two new studies were included in this update of the
original review
7 August 2009 Amended Copy edits made at editorial base.
16 September 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
MP and RB carried out and completed the update of this review. MP and RB assessed trials for eligibility and completed data extraction.
RB and MP both contributed to the writing of the review and the data analysis. KH conducted the dose regression analysis. AM
provided supervision throughout the review process.
D E C L A R A T I O N S O F I N T E R E S T
MP: none known.
RB: none known.
KH: acted as expert witness as a statistician in a number of legal cases including antiepileptic drug cases.
AM: a consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in
Hospitals (NASH) through grants paid to the University of Liverpool. Professor Tony Marson is part funded by National Institute for
Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC).
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (NIHR), UK.
This review update was supported by the National Institute for Health Research, via Cochrane Programme Grant funding to the
Epilepsy Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the
Systematic Reviews Programme, NIHR, National Health Service (NHS), or the Department of Health and Social Care.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The original protocol was amended for the previous review to include interventions comparing pregabalin to other antiepileptic drugs.
The method of analysis for examining dose regression was changed for the previous version of the review due to advances in techniques
for analysis binary data. Specifically, a generalised linear mixed model using the software package STATA SE version 14 (Stata statistical
software 2015) was employed as opposed to a generalised linear model. We continued to use a generalised linear mixed model in the
current review update.
The title of the review has been changed from “Pregabalin add-on for drug-resistant partial epilepsy” to “Pregabalin add-on for drug-
resistant focal epilepsy” in accordance with the latest classification of epilepsies released by the International League Against Epilepsy
(ILAE) (Scheffer 2017). Likewise, any previous mention of “partial epilepsy” or “refractory epilepsy” throughout this review was
changed to “focal epilepsy” and “drug-resistant epilepsy”, respectively.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [adverse effects; ∗therapeutic use]; Drug Resistance; Epilepsies, Partial [∗drug therapy]; Pregabalin; Randomized
Controlled Trials as Topic; gamma-Aminobutyric Acid [adverse effects; ∗analogs & derivatives; therapeutic use]
MeSH check words
Humans
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